

Review

Cite this article: Tomasiak B, Garbicz F, Braun M, Bieńkowski M and Jassem J (2024). Heterogeneity in precision oncology. *Cambridge Prisms: Precision Medicine*, 2, e2, 1–22
<https://doi.org/10.1017/pcm.2023.23>

Received: 09 May 2023
Revised: 25 August 2023
Accepted: 27 September 2023

Keywords:
cancer; precision oncology; genomics; tumour heterogeneity; proteomics

Corresponding author:
Jacek Jassem;
Email: jjassem@gumed.edu.pl

© The Author(s), 2023. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.



Heterogeneity in precision oncology

Bartłomiej Tomasiak¹, Filip Garbicz^{2,3,4} , Marcin Braun⁵, Michał Bieńkowski⁶ and Jacek Jassem¹ 

¹Department of Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland; ²Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA; ³Department of Experimental Haematology, Institute of Haematology and Transfusion Medicine, Warsaw, Poland; ⁴Department of Immunology, Medical University of Warsaw, Warsaw, Poland; ⁵Department of Pathology, Chair of Oncology, Medical University of Łódź, Łódź, Poland and ⁶Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland

Abstract

Precision oncology is a rapidly evolving concept that holds great promise in cancer treatment. However, a cancer complexity attributed to genomic and acquired tumour heterogeneity limits treatment effectiveness and increases toxicity. These limitations refer to both systemic therapies and radiotherapy, which are two mainstays of non-invasive cancer treatment. By understanding cancer heterogeneity and utilising advanced tools to personalise treatment strategies, precision oncology has the potential to revolutionise cancer care. In this article, we review the current status of precision oncology in solid tumours, specifically focusing on the impact of tumour heterogeneity and genomic patient features on systemic therapies and radiation. We also discuss the implementation of novel tools, such as next-generation sequencing and liquid biopsies, to overcome this problem.

Impact statement

Precision oncology, one of the most promising applications of precision medicine, uses molecular and genetic information to customise cancer treatments, considering the individual characteristics of each patient's tumour. To further advance the field, precision oncology increasingly incorporates knowledge of cancer heterogeneity, on both spatial and temporal levels. Addressing these complexities with modern precision radiotherapy and systemic therapies is the key to targeting all cancer cell subpopulations. The future vision of precision oncology involves continuous advancements in technological and analytical methods, leading to further treatment personalisation. This progress will ultimately contribute to a paradigm shift in cancer care to improve patient outcomes significantly. Access to advanced tools should be improved in terms of availability and affordability while addressing the need for routine genomic profiling across various regions of primary and metastatic tumours to understand cancer heterogeneity comprehensively.

Introduction

Precision medicine is a novel approach to treatment and prevention that tailors strategies to the unique characteristics of individual patients, including their genetics, environment and lifestyle. It differs from conventional evidence-based medicine, which generally relies on average clinical benefits in the studied populations (Tonelli and Shirts, 2017; Blackstone, 2019). Precision medicine is supported by advances in technology and medical research, such as using genomic sequencing and big data analysis to identify individualised treatment options.

The decision-making process in precision medicine is based on predictive biomarkers, which offer insights into the underlying molecular mechanisms of tumorigenesis and allow the identification of potential therapeutic targets. In clinical settings, biomarkers can predict which patients are most likely to benefit from specific therapies, optimise treatment efficacy and reduce toxicity. Further, biomarkers enable early cancer detection and treatment monitoring, thereby increasing its efficacy. In essence, biomarkers are transformative tools of personalised medicine, driving more accurate, effective and safer cancer treatments (Slikker, 2018).

The two most commonly used markers are prognostic and predictive biomarkers. A prognostic biomarker is a clinical or biological indicator that offers insights into the probable health outcome of an individual patient, such as disease recurrence or death, regardless of the treatment pursued. In turn, a predictive biomarker signifies the potential advantage to the patient, resulting from a specific treatment (Sechidis et al., 2018). Other biomarkers include predisposing biomarkers, indicating the potential for developing a disease (Califf, 2018) and pharmacogenomic biomarkers, informing about the drug efficacy and toxicity based on the underlying genetic composition (Lauschke et al., 2017). The United States Food and Drug Administration and the

National Institutes of Health published the Biomarkers, Endpoints and other Tools (BEST) resource, describing the extensive list of biomarkers used in translational science (Cagney *et al.*, 2018).

Precision oncology is a concept that customises oncological care based on unique patient genomics and clinical, genetic, proteomic, transcriptomic or phenotypic tumour features (de and Ashworth, 2010; Collins and Varmus, 2015). Precision oncology has achieved unprecedented advancements through rigorous scientific evidence and extensive computational analyses (Mirnezami *et al.*, 2012). However, challenges such as accurate data interpretation, precise patient stratification and the development of successful targeted therapies for specific genomic aberrations require further efforts (Prasad *et al.*, 2016).

To overcome these obstacles, precision oncology requires innovative clinical trial designs that account for patient and tumour heterogeneity and the dynamic nature of cancer evolution (Chen and Snyder, 2013). Integrating precision oncology into clinical practice is a key goal of the Precision Medicine Initiative, which was launched by the US government in 2015.

In the present article, we discuss the impact of tumour and patient heterogeneity on treatment outcomes in solid tumours oncology and explore how precision systemic therapies and radiotherapy can mitigate these obstacles. The analysis will focus on scrutinising pivotal studies, such as the Molecularly Aided Stratification for Tumour Eradication Research (MASTER) (Horak *et al.*, 2017), the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial (Flaherty *et al.*, 2020 and other pertinent research, to better understand customised cancer therapy. We also present current investigative endeavours and interdisciplinary collaborations to optimise cancer therapy in all patients, regardless of their genetic makeup (Topol, 2014; Jameson and

Longo, 2015; Figure 1). The examples provided here should be considered illustrative, as no comprehensive literature analysis on this topic was attempted.

Systemic therapies

Systemic therapies, which involve drugs circulating throughout the body, are fundamental to cancer treatment (Chabner and Roberts, 2005). Precision oncology has revolutionised systemic therapies by better allocating standard chemotherapy and has paved the way for specific targeted therapies (Schwaederle *et al.*, 2015). However, cancer heterogeneity, both spatial and temporal, highly impacts the effectiveness of these therapies (Greaves and Maley, 2012). As a result, one of the major challenges in oncology is customising systemic therapies for each patient and tumour characteristics (Leichsenring *et al.*, 2019).

Tumour heterogeneity

Whereas cytotoxic chemotherapy is essential for many malignancies, it is generally recognised as a one-size-fits-all approach, which may not be optimal for patients with genetically diverse tumours. Precision oncology considers tumour genetic heterogeneity, thus can improve the efficacy of standard treatments, identify druggable targets for specific tumours and select patients who are more likely to benefit from customised treatments (Massard *et al.*, 2017).

The relationship between specific genomic alterations, genetic inter- and intratumour heterogeneity and the effectiveness of cancer treatment has been well established (Schwaederle *et al.*, 2015; McGranahan and Swanton, 2017). Tumours with certain genetic




Figure 1. Timeline showing the highlights of clinical precision medicine. ALK, anaplastic lymphoma kinase; ALL, acute lymphoblastic leukaemia; BCa, breast carcinoma; BRAF, v-Raf murine sarcoma viral oncogene homologue B; BRCA, Breast Cancer gene; CAR-T, chimeric antigen receptor T-cell therapy; CML, chronic myeloid leukaemia; CR, complete response; ER+, oestrogen receptor-positive; HER2, human epidermal growth factor receptor-2; KRAS, Kirsten rat sarcoma virus; MET, hepatocyte growth factor receptor; MMRd, mismatch repair deficiency; MSI-H, high microsatellite instability; NGS, next generation sequencing; NSCLC, non-small cell lung cancer; PD-1, programmed death receptor-1; RET, Ret Proto-Oncogene; VEGF, vascular endothelial growth factor.

alterations differ in their susceptibility to classical cytotoxic chemotherapy. For example, mutations in the *TP53*, *KRAS*, *PTEN* or *RB1* genes are associated with resistance to chemotherapy (Custodio et al., 2009; Perrone et al., 2010), *BRCA1* and *BRCA2* mutations denote chemosensitivity to platinum compounds (Pennington et al., 2014), and *MGMT* methylation in glioblastoma is associated with a better response to temozolomide (Stupp et al., 2005).

Knowledge of genetic tumour heterogeneity has been extensively used in targeted cancer therapies (Figure 2). If druggable, genetic alterations are primarily used as therapeutic targets; however, many also serve as predictive markers for treatment effectiveness. In colorectal cancer, cetuximab, which is a chimeric antibody against the epidermal growth factor receptor (EGFR), is effective only against wild-type rat sarcoma (RAS) family oncogenes (Van Cutsem et al., 2009; Douillard et al., 2013). Conversely, in lung cancer, EGFR tyrosine kinase inhibitors are less effective in patients with coexisting TP53 (Aggarwal et al., 2018; Sun et al., 2023) or *KRAS* mutations (Massarelli et al., 2007), which can activate alternative signalling pathways bypassing the EGFR pathway. In breast cancer, human epidermal growth factor receptor-2 (HER2)

inhibitors are widely used to treat patients with HER2-overexpressing or HER2-amplified tumours, but they are less effective in patients with coexisting mutations in fibroblast growth factor receptor-1 (FGFR1) or receptor-2 (FGFR2) genes (Hanker et al., 2017). FGFR alterations correlate with resistance to several targeted and standard therapies across different malignancies (Babina and Turner, 2017), while the mechanistic and prognostic role of FGFR1–4 protein overexpression remains equivocal (Piasecka et al., 2019).

Some genetic alterations are druggable only in specific tumours, whereas others can be targeted across biologically and clinically different malignancies. The inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are effective and routinely administered to treat advanced hormone receptor-positive, HER2-negative breast cancer, though CDK4/6 alterations are not a hallmark of these cancers and do not predict the effectiveness of this therapy (Suski et al., 2021; Cristofanilli et al., 2022). Furthermore, CDK4/6 inhibitors are inefficient in liposarcomas harbouring the amplification of *CDK4/6* and murine double minute 2 (*MDM2*) genes (Sbaraglia et al., 2021). Other examples are ivosidenib, an isocitrate dehydrogenase-1




Figure 2. Examples of precision medicine biomarkers used in oncologic practice, together with respective targeted therapies approved in patients harbouring such lesions. CPI, checkpoint inhibitor; CTL, cytotoxic lymphocyte; DDR, DNA damage response; MMR, mismatch repair; MSI, microsatellite instability; PD-L1, programmed death-ligand 1; TMB, tumour mutational burden.

(IDH1) inhibitor, and enasidenib, an IDH2 inhibitor, which effectively targets relapsed or refractory acute myeloid leukaemia with IDH1/2 mutations (Cerchione et al., 2021) but that are not effective in gliomas bearing these mutations. In turn, some targeted therapies, for example, entrectinib, which targets neurotrophic tyrosine receptor kinase (*NTRK*) fusions, and ROS oncogene 1 (*ROS1*) rearrangements, are effective across different solid tumour types, including lung cancer, colorectal cancer and thyroid cancer (Doebele et al., 2020; Drilon et al., 2020). Similarly, V-raf murine sarcoma viral oncogene homologue B1 (*BRAF*) and mitogen-activated protein kinase (*MEK*) inhibitors were recently approved with a tumour-agnostic indication for unresectable or metastatic solid tumours harbouring the *BRAF V600E* mutation (Gouda and Subbiah, 2023).

Immune-oriented therapies, such as immune checkpoint inhibitors (ICIs) or chimeric antigen receptor T-cells (CAR-T), have revolutionised cancer treatment. However, correctly identifying good responders remains challenging. Genetic heterogeneity in tumours may elicit variable responses to ICIs. Malignancies with a high tumour mutational burden (TMB) and neoantigen load are more responsive to ICIs. Patients with high-TMB non-small cell lung cancer (NSCLC) or melanoma achieve significant improvements in survival with ICIs compared with those with low TMB (Ning et al., 2022; Ricciuti et al., 2022). However, intratumour or intersite (primary vs. metastatic foci) heterogeneity leading to spatial neoantigen expression variability might result in the escape of certain subclones from immune surveillance (McGranahan and Swanton, 2017). Different tumour types (e.g., colorectal or endometrial cancers) with microsatellite instability or mismatch repair deficiency are highly responsive to ICIs (Cercek et al., 2022; O'Malley et al., 2022), whereas tumours with some mutations may be ICI resistant. For instance, *EGFR*-mutant NSCLCs are less sensitive to ICIs than wild-type *EGFR* (Mazieres et al., 2019). Melanomas with overactive WNT/ β -catenin signalling are less infiltrated by T-cells and, thus, less susceptible to ICIs (Spranger et al., 2015).

Cancers with high levels of intrinsic heterogeneity, which can be defined as the presence of different genetic clones within a single tumour, are usually less likely to benefit from chemotherapy and targeted therapies (McGranahan and Swanton, 2017) because of the presence of drug-resistant subclones within the tumour that can contribute to rapid relapse after the initial response to therapy (Burrell et al., 2013; Almendro et al., 2014). Computational modelling and in situ analyses have shown that genetic and phenotypic heterogeneity can greatly affect tumour evolution during chemotherapy and treatment outcomes (Almendro et al., 2014). Recent advances in genomics and single-cell sequencing have shed light on the molecular mechanisms underlying tumour heterogeneity, paving the way for the development of novel personalised therapeutic strategies (Dagogo-Jack and Shaw, 2018; Ramón et al., 2020; Labrie et al., 2022). Further development of precision medicine for systemic anticancer therapies heavily relies on better understanding and addressing intratumour heterogeneity. However, because of diagnostic limitations, intratumour heterogeneity cannot yet be routinely exploited in guiding treatment options. It is expected that circulating tumour DNA (ctDNA) and single-cell analysis techniques may enable a detailed characterisation of tumour cell populations and better inform personalised treatment strategies (Nath and Bild, 2021; Tivey et al., 2022). ctDNA dynamic profiling allows for real-time monitoring of tumour evolution and adapting treatment strategies as the tumour mutates and evolves. Recently, ctDNA-guided therapy was shown to be beneficial in patients with NSCLC and colorectal cancer (Jee et al., 2022; Tie et al., 2022).

Precision medicine approaches may considerably improve cancer treatment outcomes, provided that the complex interplay between tumour genetics and response to systemic treatment is better understood. Basic and translational studies are essential for identifying next-generation predictive biomarkers. Novel clinical trial designs, such as basket-type trials assessing the druggability of specific targets across different tumour types, and umbrella-type trials evaluating the efficacy of specific or various targeted therapies in specific cancer diagnoses (Figure 3 and Table 1), may prompt the development of new tailored therapies (Subbiah, 2023).

To compile the data presented in Tables 1 and 2 (please see below), we employed a multi-pronged search strategy. Firstly, a targeted search was conducted on PubMed using the following query: ("precision medicine"[Title/Abstract] OR "targeted therapy"[Title/Abstract] OR "personalised medicine"[Title/Abstract]) AND "clinical trial"[Publication Type] AND ("2013/01/01"[PDAT]: "2023/12/31"[PDAT]). This query was designed to yield articles classified as "clinical trials" focusing on "precision medicine," "targeted therapy," or "personalised medicine," and published between January 1, 2013, and December 31, 2023. In addition to PubMed, we supplemented the articles with data from the clinical trials registry [ClinicalTrials.gov](https://clinicaltrials.gov) and information gathered from sessions at the European Society for Medical Oncology (ESMO) Meetings and American Society of Clinical Oncology (ASCO) Annual Meetings held between 2018 and 2023. These conferences are recognised platforms that regularly feature key developments in precision medicine trials in oncology.

Germline heterogeneity

Response and adverse reactions to systemic therapies can vary substantially between individuals. This variability has been attributed mainly to the inherited genomic variants that inactivate protein-coding genes (Karczewski et al., 2020). The therapy may be impacted on several levels, including direct drug–target interactions, drug metabolism (including drug activation and removal) and downstream effects (e.g., DNA damage). Hence, considering patient pharmacogenomics can improve treatment outcomes, decrease toxicity and reduce costs.

The drug-metabolising enzyme known as cytochrome P450 2D6 (CYP2D6) is the most thoroughly examined and variable polymorphic enzyme (Zhou and Lauschke, 2022). Its deficiency is inherited through an autosomal recessive trait, and individuals carrying this alteration are classified as poor metabolisers. However, the remaining subjects (extensive metabolisers) display considerable variability in their enzymatic activity (Bertilsson et al., 2002). The gene encoding the CYP2D6 protein is highly polymorphic, with over 100 allelic variants described to date (Gaedigk et al., 2018). Specific genetic variations in the CYP2D6 gene can cause altered activity of the cytochrome P450 2D6 enzyme, which is involved in the metabolism of tamoxifen (a selective oestrogen modulator used to treat breast cancer). Individuals with reduced CYP2D6 activity (e.g., *4, *5 and *6 alleles) account for up to 10% of patients (Ingelman-Sundberg, 2004; Crews et al., 2014). These individuals have a lower efficacy of tamoxifen than those with normal activity (Lim et al., 2007; Schroth et al., 2007; Goetz et al., 2013). Likewise, the ultrarapid metabolisers (e.g., with *1xN or *2xN alleles, about 1–2% of patients) show lower endoxifen (a tamoxifen metabolite) concentrations and worse outcomes compared with patients with normal CYP2D6 activity (Wegman et al., 2005; Schroth et al., 2007; Crews et al., 2014).




Figure 3. Types of precision medicine clinical trials. BRAF, v-Raf murine sarcoma viral oncogene homologue B; SOC, standard of care.

Similarly, variations in the *DPYD* gene (e.g., *2A or *13), which encodes the dihydropyrimidine dehydrogenase, an enzyme involved in the metabolism of fluoropyrimidines, such as 5-fluorouracil and capecitabine, can lead to reduced enzyme activity and an increased risk of severe toxicity (Amstutz et al., 2009; Offer et al., 2014; Henricks et al., 2018).

Finally, the *UGT1A1* gene, which encodes for the uridine diphosphate glucuronosyltransferase 1A1 enzyme, is involved in the metabolism of irinotecan (a topoisomerase I inhibitor); variations reducing its activity (including *6, *27 and *28) may cause severe toxicity, including neutropenia, diarrhoea or infection (Iyer et al., 2002; Innocenti et al., 2004; Marcuello et al., 2004; Xu et al., 2016).

Genomic polymorphisms in drug targets may also affect interactions with drugs. Several *HER2* gene variants have been shown to impact the effectiveness of trastuzumab (a monoclonal antibody targeting *HER2*) in *HER2*-positive breast cancer patients. The F117L variant, which is located in the extracellular domain of the *HER2* protein, impairs trastuzumab binding by approximately threefold compared with wild-type *HER2*. Decreased binding affinity is attributed to the introduction of a leucine residue, which causes a steric hindrance and disrupts the protein conformation at the binding site (Gaborit et al., 2011). In turn, a variant within the *HER2* intracellular kinase domain (T798I) leads to increased kinase activity, conferring resistance to lapatinib (Bose et al., 2013). Another example of *EGFR* polymorphism is R521K (rs2227983),

which may decrease the response to cetuximab in patients with metastatic colorectal cancer (Graziano et al., 2008). As a result, patients who carry this allele experience a lower incidence of skin toxicity during cetuximab treatment (Klinghammer et al., 2010; Fernández-Mateos et al., 2016).

Finally, variants affecting the efficiency of DNA damage repair may affect the response and toxicity of numerous drugs, including platinum agents, alkylating agents, topoisomerase II inhibitors, antimetabolites and poly-ADP ribose polymerase inhibitors. The rs3212986 variant (C8092A) of the *ERCC1* gene, which is a component of the nucleotide excision repair pathway, is associated with a poor response to platinum agents in NSCLC and ovarian cancer (Zhou et al., 2004; Krivak et al., 2008). Similarly, the rs13181 (L751G) single nucleotide variant (SNV) in the *XPD* gene is associated with the poor efficacy of platinum agents in NSCLC (Park et al., 2001).

Radiotherapy

Radiotherapy is a vital component of cancer treatment, applicable in around 60% of patients (Citrin, 2017). Until recently, radiotherapy was prescribed on the empirical basis of a one-fits-all approach, assuming a similar response to the same radiation dose. Recent advances in precision medicine have enabled the use of more

Table 1. Selected clinical trials investigating personalised cancer therapies

Trial ID/Name	Patient population	Intervention	Precision technologies	Study design	Primary endpoint	N	Results
<i>MASTER</i> (Molecularly Aided Stratification for Tumour Eradication Research) (Horak et al., 2021)	Adults with advanced solid tumours (age < 51 years) and patients with rare tumours, including rare subtypes of more common entities, regardless of age (221 different ICD-O-3 codes), who exhausted curative treatment options	Evaluation of biomarkers' clinical actionability and assignment of molecularly informed therapies in semiweekly, multicentre MTB conferences	WES, WGS, RNA-seq	Multicentre, prospective observational study – master observational trial (Dickson et al., 2020)	PFSr	1,310	Of 300 patients evaluable for PFSr, 107 (35.7%) had a PFSr >1.3
<i>NCI-MATCH</i> (Molecular Analysis for Therapy Choice) (Flaherty et al., 2020)	Adults (age ≥ 18 years) with advanced solid tumours, lymphomas or myelomas that have progressed after standard treatments or for whom no standard treatment is available	Targeted therapies matched to specific genetic tumour abnormalities. Patients are assigned to different treatment arms based on the genetic alterations found in their tumours	Oncomine Cancer Panel (Lih et al., 2017) based on FFPE-extracted DNA and RNA, IHC (Khoury et al., 2018)	Phase 2, non-randomised, open-label, multicentre clinical trial	ORR	1,201	Arms: <ul style="list-style-type: none"> <i>Z1B</i> (palbociclib in BCa with amp CCND1/2/3: ORR 0% (Clark et al., 2023)) <i>B</i> (afatinib in pts. with <i>EGFR2</i>-activating mutations): ORR 2.7% (Bedard et al., 2022) <i>F</i> (crizotinib in <i>ALK</i>-rearranged ca): ORR 50% <i>G</i> (crizotinib in <i>ROS1</i>-rearranged ca): ORR 25% (Mansfield et al., 2022) <i>I</i> (taselisib in <i>PIK3CA</i>-mutated ca other than BCa and SCC): ORR 0% (Krop et al., 2022) <i>Z1F</i> (copanlisib in <i>PIK3CA</i>-mut ca): ORR 16% (Damodaran et al., 2022) <i>Z1A</i> (binimetinib in <i>NRAS</i>-mut ca excluding melanoma): ORR 2.1% (Cleary et al., 2021) <i>Y</i> (capiwasertib in <i>AKT1 E17K</i>-mut ca): ORR 29% (Kalinsky et al., 2021) <i>H</i> (dabrafenib and trametiib in <i>BRAFV600E</i>-mut ca): ORR 38% (Salama et al., 2020) <i>W</i> (AZD4547 in <i>FGFR</i> amp/mut/tx ca): ORR 8% (Chae et al., 2020) <i>R</i> (trametinib in non-V600 <i>BRAF</i> mut ca): ORR 3% (Johnson et al., 2020) <i>Z1D</i> (nivolumab in MMRd ca): ORR 36% (Azad et al., 2020) <i>Q</i> (Ado-trastuzumab emtansine in HER2-amp ca excluding BCa and GEJ adenoCa): ORR 5.6%
<i>TAPUR</i> (Targeted Agent and Profiling Utilisation Registry) (NCT02693535) (Mangat et al., 2018)	Patients (age ≥ 12 years) with histologically-proven locally advanced or metastatic solid tumours, multiple myeloma or B cell non-Hodgkin lymphoma who are no longer benefiting from standard anticancer treatment or no such treatment is available or indicated	FDA-approved targeted therapies (usually used for other cancer types) matched to the specific genomic alterations in a patient's tumour	NGS	Phase 2, non-randomised, open-label, multicentre clinical trial	ORR	3,581 (planned)	Two arms closed at stage I because of a lack of responses; 12 arms expanded to stage II <ul style="list-style-type: none"> <i>ALK, ROS1, MET</i> – crizotinib <i>CDKN2A, CDK4, CDK6</i> – palbociclib or abemaciclib <i>CSF1R, PDGFR, VEGFR</i> – sunitinib <i>mTOR, TSC</i> – temsirolimus <i>BRAF V600E/D/K/R</i> – vemurafenib and cobimetinib <i>RET, VEGFR1/2/3, KIT, PDGFRβ, RAF-1, BRAF</i> - regorafenib <i>BRCA1/2, ATM</i> – olaparib <i>NRG1</i> Afatinib

(Continued)

Table 1. (Continued)

Trial ID/Name	Patient population	Intervention	Precision technologies	Study design	Primary endpoint	N	Results
							<ul style="list-style-type: none"> • <i>BRCA1/2</i>, <i>PALB2</i> – talazoparib • <i>ROS1</i> fusion – entrectinib • <i>NTRK</i> amplification – larotrectinib
<i>I-PREDICT</i> (Profile Related Evidence Determining Individualised Cancer Therapy) (NCT02534675) (Sicklick et al., 2019)	Adults (age ≥ 18 years) with advanced or metastatic solid tumours that have progressed after standard treatments or for which no standard treatment is available	Personalised targeted therapies and combination treatments based on genomic tumour profiling; the treatment plan designed by a molecular tumour board using DNA sequencing and other molecular analysis techniques to identify actionable genomic alterations	Tissue genomic profiling using NGS (Foundation Medicine; 236–405 genes), PD-L1 IHC, TMB, MSI status, ctDNA	Phase 2, single-arm, open-label, prospective clinical trial	ORR	149	ORR 11.4% A High Matching Score was an independent predictor of higher DCR (OR 3.6; 95% CI 1.1–11.8; $p = 0.033$)
<i>MyPathway</i> (NCT02091141)	Adults (age ≥ 18 years) with advanced solid tumours that have progressed after standard treatments or for which no standard treatment is available	Targeted therapies that are matched to specific molecular tumour alterations. The trial investigates the off-label use of targeted therapies which are FDA-approved for other cancer indications	IHC, FISH, NGS, FoundationOne CDx	Tissue-agnostic, non-randomised, phase 2a multiple basket trial	ORR	357 13 70 37 21 43	Arms: <ul style="list-style-type: none"> • <i>HER2</i> (trastuzumab + pertuzumab in <i>HER2</i>-altered ca): ORR 23.3% • <i>EGFR</i> (erlotinib in <i>EGFR</i>-mut. ca): ORR 7.7% • <i>BRAF</i> (vemurafenib ± cobimetinib in <i>BRAF</i>-mut. ca): ORR 24.3% • <i>Hh</i> (vismodegib in <i>PTCH1/SMO</i>-mut. ca): ORR 10.8% • <i>ALK</i> (alectinib in <i>ALK</i>-driven ca.): ORR 30% • <i>TMB</i> (atezolizumab in TMB-high ca): ORR 39.5% (Friedman et al., 2022)
<i>LUNG-MAP</i> (Lung Cancer Master Protocol) (NCT02154490) (Redman et al., 2020)	Adults (age ≥ 18 years) with advanced or metastatic squamous or non-squamous NSCLC who have progressed after first-line standard therapy	Targeted therapies and immunotherapies matched to specific tumour molecular alterations. The trial investigates the use of these therapies in patients with advanced NSCLC who have progressed after first-line standard therapy	NGS (FoundationOne) IHC	Phase 2/3, randomised, open-label, multicentre clinical trial	ORR; OS in phase 3 substudies	1864	Substudies: <ul style="list-style-type: none"> • <i>S1400A</i> (durvalumab vs. docetaxel) • <i>S1400B</i> (taselisib vs. docetaxel in <i>P13KCA</i>-mut. ca) • <i>S1400C</i> (palbociclib vs. docetaxel in <i>CDK4/6</i>, <i>CCND1/2/3</i>-positive ca) • <i>S1400D</i> (AZD4547 vs. docetaxel in pts. positive for <i>FGFR1/2/3</i>) • <i>S1400E</i> (rilotumumab + erlotinib vs. erlotinib in <i>HGF/c-MET</i>-pos. ca) • <i>S1400F</i> (durvalumab + tremelimumab) • <i>S1400G</i> (talazoparib in HHR-deficient ca) • <i>S1400I</i> (nivolumab + ipilimumab vs. nivolumab)
<i>BATTLE</i> (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination) (E.	Adults (age ≥ 18 years) with advanced NSCLC who have progressed after first-line platinum-based chemotherapy	Erlotinib (an <i>EGFR</i> inhibitor), vandetanib (a <i>VEGFR</i> inhibitor), erlotinib plus bexarotene (a retinoid X receptor agonist) and sorafenib (a multikinase inhibitor). Patients assigned to one of these treatments based on the molecular	FISH, IHC, Sanger sequencing	Phase 2, adaptive, randomised, open-label clinical trial	8-week DCR	255	The 8-week 46% DCR for the entire study population, with the following rates for each treatment arm: <ul style="list-style-type: none"> • erlotinib: 43% • vandetanib: 39% • erlotinib plus bexarotene: 50% • sorafenib: 53%

(Continued)

Table 1. (Continued)

Trial ID/Name	Patient population	Intervention	Precision technologies	Study design	Primary endpoint	N	Results
S. Kim et al., 2011)		tumour profile, assessed using biomarkers, such as EGFR, KRAS, VEGF and cyclin D1					
<i>SHIVA</i> (NCT01771458) (Le Tourneau et al., 2015)	Adults (age ≥ 18 years) with advanced solid tumours that have progressed after standard treatments or for which no standard treatment is available	Patients randomised into two groups: the experimental group receiving molecularly targeted agents based on tumour molecular profiling, and the control group receiving treatment according to the physician's choice	Targeted NGS, Cytoscan copy number analysis	Phase 2, open-label, randomised, controlled clinical trial	PFS	293	Median PFSI 2.3 months (95% CI 1.7–3.8) in the experimental group vs. 2.0 months (1.8–2.1) in the control group (hazard ratio 0.88, 95% CI 0.65–1.19, <i>p</i> = 0.41)
<i>WINTHER</i> (Worldwide Innovative Networking in Personalised Cancer Medicine) (NCT01856296)	Adults (age ≥ 18 years) with advanced solid tumours that have progressed after standard treatments or for which no standard treatment is available	Personalised targeted therapies and chemotherapies that are matched to specific genomic alterations or gene expression patterns in the patient's tumour	Fresh biopsy: DNA + RNA NGS testing	Phase 2, non-randomised, open-label, multicentre clinical trial	PFSr	107	The trial did not meet its primary endpoint, as the PFS ratio of ≥1.5 was observed in only 22% of patients in Arm A (DNA-seq-based drug matching) and 26% in Arm B (RNA-seq-based drug matching)
<i>GBM AGILE</i> (Glioblastoma Adaptive Global Innovative Learning Environment) (NCT03970447) (Alexander et al., 2018)	Adults (age ≥ 18 years) with newly diagnosed or recurrent glioblastoma	Targeted therapies and immunotherapies, which are compared to standard treatment options. The specific agents tested in the trial may change over time as new treatments become available or others are dropped based on their performance in the study	NR	Phase 2/3, adaptive, randomised, open-label, multicentre clinical trial	PFS/OS	NR	NR
<i>FOCUS4</i> (Brown et al., 2022)	Adults (age ≥ 18 years) with advanced colorectal cancer who have completed 16 weeks of first-line chemotherapy	Patients are first treated with standard chemotherapy and then, based on their molecular subtyping, are randomised into different treatment arms; the trial tests these targeted therapies against a control group receiving standard treatment or a placebo, and the specific agents tested in the trial may change over time as new treatments become available or others are dropped based on their performance in the study	Pyrosequencing, NGS, IHC (Richman et al., 2022)	Phase 2/3, randomised, open-label, multicentre clinical trial	PFS/OS	361	FOCUS4-D (sapitinib in <i>BRAF-PIK3CA-RAS</i> wt ca) closed FOCUS4-B (aspirin in <i>PIK3CA</i> -mut. ca) closed FOCUS4-C (adavosertib in <i>RAS + TP53</i> double mutant) (Seligmann et al., 2021) FOCUS4-N (nonstratified). Median PFS in the capecitabine arm 3.9 months (95% CI 3.7–4.4) and 1.9 months (95% CI 1.8–2.1) in the AM arm/Unadjusted and adjusted HRs 0.44 (95% CI 0.33–0.57), <i>p</i> < 0.0001 and 0.40 (95% CI 0.21–0.75), <i>p</i> < 0.0001, respectively

(Continued)

Table 1. (Continued)

Trial ID/Name	Patient population	Intervention	Precision technologies	Study design	Primary endpoint	N	Results
<i>NCI-COG Paediatric MATCH NCT03155620</i>	Children and adolescents (aged 1–21 years old) with recurrent, refractory or progressive solid tumours, lymphomas and histiocytic disorders	Molecularly targeted therapies matched to specific tumour genetic alterations	DNA and RNA sequencing, IHC (Parsons et al., 2022)	Phase 2, open-label, multicentre clinical trial	ORR	2,316 (planned) 20 20 20	Subprotocols: <ul style="list-style-type: none"> A (larotrectinib in ca with <i>NTRK</i> fusions) B (erdafitinib in ca with <i>FGFR1/2/3/4</i> mutation) C (patients with an <i>EZH2</i>, <i>SMARCB1</i> or <i>SMARCA4</i> mutation receive tazemetostat) ORR: 1 response (Chi et al., 2022) D (samotolisib in patients with <i>TSC1</i>, <i>TSC2</i> or <i>PI3K/mTOR</i> mutations) E (selumetinib in <i>MAPK</i>-mut. ca) ORR 0% (Eckstein et al., 2022) F (ensartinib in ca with <i>ALK</i> or <i>ROS1</i> alterations) G (vemurafenib in <i>BRAF V600E</i>-pos. ca) H (olaparib in pts. with <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>RAD51C</i> or <i>RAD51D</i> mut.) I (palbociclib in pts. with <i>Rb</i>-positive ca) J (ulixertinib in pts. with <i>MAPK</i>-mut. ca) (Vo et al., 2022): ORR 0% K (ivosidenib in ca with <i>IDH1</i> mutations) M (tipifarnib in ca with <i>HRAS</i> alterations) N (selpercatinib in ca with <i>RET</i> alterations)
<i>SAFIRO2-BREAST (NCT02299999)</i> (Mosele et al., 2020; Andre et al., 2022)	Adult women (age ≥ 18 years) with metastatic breast cancer who have progressed after standard treatments or for whom no standard treatment is available	Molecularly targeted therapies matched to specific genomic alterations in the patient's tumour	NGS, CGH array	Phase 2, open-label, multicentre clinical trial	PFS	436 157 50 40 20 17 17 7 3 3 131 148	Arms: Arm A1 (targeted arm): Patients in this arm received targeted maintenance therapy guided by genomic analysis. The therapy used eight targeted drugs. ORR: 26/157 <ul style="list-style-type: none"> Capivasertib in <i>PI3K/AKT</i>-altered ca Olaparib in <i>BRCA/DDR</i>-altered ca Alpelisib in <i>PI3KCa</i>-mut ca Selumetinib in <i>MAPK</i>-altered ca AZD4547 in <i>FGFR</i>-mut. ca Vistusertib in <i>mTOR</i>-altered ca Sapitinib in <i>HER2/3</i>-altered ca Vandetanib Arm A2 (immunotherapy arm): Patients in this arm received durvalumab Arm B (standard maintenance chemotherapy): Patients in this arm received standard maintenance chemotherapy. ORR 9/81 (Bachelot et al., 2021) After a median follow-up of 21.4 months (90% CI: 17.9–27.6), patients with ESCAT I/II showed a significantly longer PFS in the targeted therapy arm than in the control arm, with a median PFS of 9.1 months (90% CI 7.1–9.8) and 2.8 months (90% CI 2.1–4.8), respectively (adjusted HR = 0.41, 90% CI 0.27–0.61; $p < 0.001$)

(Continued)

Table 1. (Continued)

Trial ID/Name	Patient population	Intervention	Precision technologies	Study design	Primary endpoint	N	Results
<i>IMPACT</i> (Integrated Molecular Profiling in Advanced Cancers Trial) NCT01505400 (Stockley et al., 2016) <i>COMPACT</i> (Community Molecular Profiling in Advanced Cancers Trial)	Adults (age ≥ 18 years) with histological confirmation of advanced breast, non-small cell lung, colorectal, genitourinary, pancreatobiliary gastrointestinal, upper aerodigestive tract, gynaecological, melanoma, unknown primary, and rare carcinomas who are candidates for systemic therapy, as well as patients who are phase 1 trial candidates	Two parallel trials that aim to identify molecular alterations in patients' tumours and match them to targeted therapies, with <i>IMPACT</i> being conducted at academic centres and <i>COMPACT</i> in community settings	Targeted NGS panel and MALDI-TOF-based multiplex genotyping panel	Retrospective cohort study	NR	1893	ORR higher in patients treated on genotype-matched (19%) than in genotype-unmatched trials (9%; $p = 0.026$). In multivariate analysis, trial matching according to genotype ($p = 0.021$) and female gender ($p = 0.034$) were the only statistically significant factors associated with response. Genotype-matched trial patients were more likely to achieve the best response of any shrinkage in the sum of their target lesions (62%) compared with genotype-unmatched trial patients (32%; $p < 0.001$)
<i>MOSCATO 01</i> (Massard et al., 2017)	Adults (age ≥ 18 years) with advanced solid tumours that have progressed after standard treatments or for whom no standard treatment is available	Molecularly targeted therapies that are matched to specific genomic alterations in the patient's tumour	aCGH, WES, RNA-seq	Phase 2, non-randomised, open-label, multicentre clinical trial	PFSr	843	Molecular profiling and matching patients to targeted therapies led to an improvement in the ORR (11% vs. 5%) and PFS. Progression-Free Survival Ratio (PFS2/PFS1) >1.3 in 33% of patients. Following targeted therapy, of the evaluable patients, two had CR and 20 PR
<i>INFORM</i> (individualised Therapy FOR Relapsed Malignancies in Childhood) (van Tilburg et al., 2021)	Children and adolescents (age ≤ 21) with relapsed or refractory malignancies, including solid tumours, lymphomas and central nervous system tumours	Molecularly targeted therapies and immunotherapies matched to specific genomic alterations and immunological tumour features	WES, lcWGS, RNA sequencing, RNA-based gene expression array and DNA-methylation	Prospective, noninterventional, multicentre, multinational and feasibility registry	NR	519	No significant differences in PFS and OS in all patients who did and did not receive a matched targeted drug
<i>MINDACT</i> (Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy)	Women (age ≥ 18 years) with histologically proven, operable, invasive, early-stage breast cancer who have node-negative or 1 to 3 positive lymph nodes	Use of a 70-gene signature (MammaPrint) to determine the likelihood of distant recurrence in women with early-stage breast cancer. The trial compared the outcomes of patients assigned to adjuvant chemotherapy based on the traditional clinical-pathological assessment and the MammaPrint assay	MammaPrint	Phase 3, randomised, controlled, multicentre clinical trial	5-year DMFS rate	6,693	The primary endpoint was met; the inferior margin of 92.5% for DMFS at 60 months in the targeted subjects exceeded the 92% pre-specified threshold
<i>ALCHEMIST</i> (Adjuvant Lung Cancer Enrichment Marker Identification)	Adults (age ≥ 18 years) with surgically resected stage IB, II or IIIA NSCLC	Three separate subtrials, each using a specific targeted therapy based on the presence of particular tumour genomic alterations. Investigated targeted	EGFR sequencing, ALK FISH, PD-L1 IHC	Three integrated, phase 3, randomised, double-blind, placebo-controlled clinical trials	OS	4,405	NR

(Continued)

Table 1. (Continued)

Trial ID/Name	Patient population	Intervention	Precision technologies	Study design	Primary endpoint	N	Results
and Sequencing Trial)		therapies: erlotinib (for patients with EGFR mutations), crizotinib (for patients with ALK rearrangements) and nivolumab (for patients with high PD-L1 expression)					
<i>DRUP</i> (The Drug Rediscovery Protocol) (NCT02925234) (Hoes et al., 2022)	Adults (age > 18 years) with a histologically-proven locally advanced or metastatic solid tumour, multiple myeloma, or B cell non-Hodgkin lymphoma who are no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated	The molecular profiling test results are used to determine appropriate drugs from those available in the protocol. The choice of the drug is supported by a list of potential profiles, a molecular tumour board, a knowledge library, and study coordinators for review and approval of the match	Fresh biopsy: WGS; off-label use	Phase II, prospective, non-randomised basket trial	ORR	1,550 (planned)	NR
<i>TARGET</i> (Tumour Characterisation to Guide Experimental Targeted Therapy) (NCT04723316) (Rothwell et al., 2019)	Patients aged 16 years or over with confirmed diagnosis of advanced solid cancer	The primary aim of <i>TARGET</i> National is to establish a national framework to offer molecular profiling of circulating tumour DNA and/or tumour tissue (optional) to patients with advanced solid cancers	ctDNA testing	Prospective observational trial	Number of patients matched to a trial of an experimental therapeutic agent based on molecular findings from ctDNA or tumour	6,000 (planned)	NR
<i>TAPISTRY</i> (Tumour-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You) (NCT04589845)	Patients with confirmed diagnosis of advanced and unresectable or metastatic solid malignancy	Study evaluating the efficacy and safety of targeted therapy or immunotherapy, as single agents or in combination, in patients with unresectable, locally advanced or metastatic solid tumours divided into cohorts based on biomarkers	NGS, FoundationOne CDx / FoundationOne Liquid CDx-based assays	Phase II, global, multicenter, open-label, multi-cohort trial	ORR	770 (planned)	NR

ALK, anaplastic lymphoma kinase; CBR, clinical benefit rate; CI, confidence interval; ctDNA, circulating tumour DNA; DCR, disease control rate; DMFS, distant metastasis-free survival; DNA, deoxyribonucleic acid; EGFR, epidermal growth factor receptor; FDA, Food and Drug Administration; FFPE, formalin-fixed, paraffin-embedded; ICD – O, International Classification of Diseases for Oncology; IHC, immunohistochemistry; KRAS, Kirsten Rat Sarcoma Viral oncogene homologue; MSI, microsatellite instability; MTB, molecular tumour board; NGS, next-generation sequencing; NR, not reported; NSCLC, non-small cell lung cancer; OR, odds ratio; ORR, objective response rate; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; PFSr, PFS interval associated with molecularly informed therapy (PFS2) divided by the PFS interval associated with the last prior systemic therapy (PFS1); RNA, ribonucleic acid; RNA-seq, RNA sequencing; TMB, tumour mutational burden; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; WES, whole exome sequencing; WGS, whole genome sequencing.

targeted and personalised radiotherapy regimens tailored to the specific characteristics of individual patients and their tumours. Cancer heterogeneity poses a significant challenge for radiotherapy, as it can cause variable tumour responses and the emergence of radioresistant cell populations. Precision radiotherapy, by considering the comprehensive molecular and genetic tumour makeup, may overcome these challenges and allow for the development of tailored treatment plans. By integrating genomic data and other biomarkers, precision radiotherapy has the potential to maximise tumour control while minimising toxicity to surrounding healthy tissues.

Tumour response

Technological advancements in radiotherapy have increased the potential of physical radiation tailoring to personalise treatment. However, the optimisation process typically focuses on dose conformality, ignoring biological factors and assuming that all tumours react similarly to radiation (Price *et al.*, 2023). Unlike medical oncology, where genomic signatures have become part of routine practice (e.g., MammaPrint tests, Oncotype DX or PAM50), their use in radiotherapy has been limited (Parker *et al.*, 2023). Meanwhile, radiation impacts several molecular pathways, such as DNA damage, hypoxia or proliferation (Reisz *et al.*, 2014; Wang *et al.*, 2018; Huang and Zhou, 2020).

Several somatic mutations have already been established as conferring radioresistance. Numerous studies, including breast (Jameel *et al.*, 2004), colorectal (Munro *et al.*, 2005) and head and neck cancers (Hutchinson *et al.*, 2020), gliomas (Werbrouck *et al.*, 2019) and sarcomas (Casey *et al.*, 2021) have shown that *TP53* mutations might impair radiotherapy response. Other notable examples are *KEAP1* and *NFE2L2/NRF2* mutations in NSCLC and head and neck cancers (Binkley *et al.*, 2020; Guan *et al.*, 2023). In addition, the coexistence of *KRAS* and *SMAD4* mutations is an indicator of radioresistance in cervical cancer (Oike *et al.*, 2021).

To date, there has been scarce data on molecular predictive signatures in radiotherapy. These examples comprise the PORTOS classifier encompassing 24 genes to predict the efficacy of post-operative radiotherapy in prostate cancer (Zhao *et al.*, 2016) and the Adjuvant Radiotherapy Intensification Classifier (ARTIC) and POLAR classifiers, which incorporate 27 and 16 genes, respectively, to predict outcomes of postoperative radiotherapy in breast cancer (Sjöström *et al.*, 2019, 2023).

Unlike PORTOS or POLAR, which relate to specific cancers and clinical situations, a radiosensitivity index (RSI) has also been proposed as a pan-cancer and specific marker of cellular radiosensitivity. This index is based on the expression of 10 genes (*AR*, *c-JUN*, *STAT1*, *PKC*, *Rel A*, *cABL*, *SUMO1*, *CDK1*, *HDAC1* and *IRF1*) related to DNA damage response, cell cycle, apoptosis and proliferation (Eschrich *et al.*, 2009). Based on RSI, a quantitative metric for the biological effect of RT, the genomic-adjusted radiation dose (GARD) has been developed. GARD was initially validated in patients with breast cancer, lung cancer, pancreatic cancer and glioblastoma (Scott *et al.*, 2017). This signature was further tested in a pooled, retrospective, pan-cancer cohort and reported as a continuous variable associated with time to first recurrence and overall survival (Scott *et al.*, 2021). Recently, GARD has been employed in a provocative *in silico* analysis to explain the unexpected results of the seminal RTOG 0617 trial (unsuccessful radiotherapy dose escalation in locally advanced NSCLC) (Scott *et al.*, 2021). The authors assumed that this model allows for deriving an optimal radiation dose in each patient. Another study employing

prospectively collected tissues showed that low RSI values (denoting higher radiosensitivity) are associated with increased immune infiltration and activation (Grass *et al.*, 2022). Recently, based on the reanalysis of the publicly available datasets – Merged Microarray-Acquired Dataset (Bin Lim *et al.*, 2019) and the Cancer Genome Atlas (Weinstein *et al.*, 2013) – RSI was shown to be associated with immune-related features and predicted response to PD-1 blockade (Dai *et al.*, 2021). However, a recent analysis showed that RSI is not associated with survival and should not be used for radiation dose adjustments (Mistry, 2023). It was also suggested that the RSI of tumour clones remaining after RT, instead of the initial tumour population, should be evaluated to better predict the RT outcome (Alfonso and Berk, 2019).

Incorporating genomic signatures in radiotherapy decision-making has shown significant advancement through recent research, such as the GARD-based trial, to optimise radiotherapy for triple-negative breast cancer (NCT05528133). The European Organisation for Research and Treatment of Cancer has appraised the evidence from RSI/GARD studies as a priority for phase 3 clinical trials in radiotherapy (Thomas *et al.*, 2020). However, the clinical utility of these approaches warrants an evaluation that integrates molecular data into prospective clinical trials and routine clinical practice (Table 2).

Radiotherapy tolerance

The impact of genetic heterogeneity on normal tissue toxicity following radiotherapy is a significant concern in cancer treatment. Individual genetic variations can influence the severity of radiation-induced side effects (Barnett *et al.*, 2009). Normal tissue complications can range from mild to severe and may include skin reactions, inflammation, fibrosis and organ dysfunction (Bentzen, 2006). However, except for several radiosensitivity syndromes related to biallelic pathogenic mutations in DNA repair genes and deleterious heterozygous ATM mutations in young patients, no genomics-guided radiotherapy is currently used (Bergom *et al.*, 2019).

Since the beginning of the twenty-first century, more than 100 articles analysing the impact of DNA sequence changes on the frequency and severity of radiation-induced complications have been published (Andreassen *et al.*, 2016). Most of these studies have addressed SNVs, which typically affect the genes responsible for processes such as DNA break or inflammation. However, these studies were usually small (median of approximately 150 patients), hence lowering the statistical power for comparisons (Andreassen *et al.*, 2016).

To reduce the bias associated with the publication of numerous low-quality studies, the Radiogenomics Consortium (<https://epi.grants.cancer.gov/radiogenomics/>) was created in 2009 (West *et al.*, 2010). This initiative allowed for assembling adequate groups of patients with diverse clinical characteristics and validating presumed associations of SNVs with radiation toxicity. However, the results of the prospective study published in 2012 were a huge disappointment because none of the reported relationships (98 SNVs in 46 genes) were confirmed (Barnett *et al.*, 2012). However, this experience prompted the development of research employing large-scale techniques such as genome-wide association studies (GWAS). As a result, potentially interesting SNV associations with radiation reactions were found, such as variants at the locus of the *TANC1* gene that was found to be encoding a protein responsible for muscle cell regeneration (Fachal *et al.*, 2014). The strength of these associations is much higher, with odds ratios of 1.3–1.5, compared with 1.1–1.2 observed in typical GWAS studies

Table 2. Summary of selected clinical studies investigating radiosensitivity-predicting genomic signatures

Study	Cancer type	Sample size	Main findings
Zhao et al., 2016	Prostate cancer	526 patients (196 and 330 in training and validation cohorts, respectively)	24-gene predictor of response to postoperative RT. High PORTOS score predicted a lower incidence of distant metastases in both training (HR 0.12; 95%CI: 0.03–0.41; $p < 0.0001$) and validation (HR 0.15; 95% CI 0.04–0.60; $p = 0.002$) cohorts
Tang et al., 2017	Sarcomas	253 patients from The Cancer Genome Atlas	26-gene radiosensitivity signature. Predicted radiosensitive patients had better overall survival than predicted nonradiosensitive patients (HR 0.07, $p < 0.001$)
Cui et al., 2018	Breast cancer	948 and 1,439 patients in the training and validation cohorts, respectively (METABRIC)	34-gene radiosensitivity signature. Patients administered RT had better disease-specific survival than those who did not in the radiation-sensitive group (HR 0.68, $p = 0.059$); a reverse effect was observed in the radiation-resistant group (HR 1.53, $p = 0.059$) 4-gene immune signature predictive of RT benefit. Patients who were administered RT had significantly better disease-specific survival in the immune-effective group (HR 0.46, $p = 0.0076$), with no difference in disease-specific survival in the immune-defective group (HR 1.27, $p = 0.16$)
Sjöström et al., 2019	Breast cancer	748 patients from the SweBCG91-RT trial	Adjuvant Radiotherapy Intensification Classifier (ARTIC) comprising 27 genes and patient age was prognostic for locoregional recurrence in breast cancer patients administered RT (HR 3.4; 95% CI: 2.0 to 5.9; $p < 0.001$) and was predictive of RT benefit ($p = 0.005$). Patients with low ARTIC scores had a larger benefit from RT (HR 0.33; 95% CI: 0.21 to 0.52, $p < 0.001$) than those with high ARTIC scores (HR 0.73; 95% CI: 0.44 to 1.2, $p = 0.23$)
Kim et al., 2020	HPV-negative head and neck squamous cell carcinomas	203 patients from The Cancer Genome Atlas (TCGA) cohort	41-gene radiation sensitivity signature (RSS). RSS predicted reduced 5-year recurrence-free survival in the radioresistant group versus the radiosensitive group (57.8% vs. 80.1%; $p = 0.035$)
Scott et al., 2021	Various types (breast, head and neck, NSCLC, pancreatic, endometrial, melanoma and glioma)	1,615 patients, of whom 1,298 (982 and 316 with and without RT, respectively) assessed for time to first recurrence and 677 (424 and 253 with and without RT, respectively) for overall survival	Genomic-adjusted radiation dose (GARD) was associated with time to first recurrence (HR 0.98, 95% CI 0.97–0.99; $p = 0.0017$) and overall survival (HR 0.97, 0.95–0.99; $p = 0.0007$). The effect on overall survival was dependent on radiotherapy use ($p = 0.011$)
Feng et al., 2021	Prostate cancer	486 of 760 patients randomised in NRG/RTOG 9601 trial	22-gene genomic classifier Decipher (Decipher Biosciences Inc) was associated with distant metastases (HR 1.17; 95%CI: 1.05–1.32; $p = 0.006$), prostate cancer-specific mortality (HR 1.39; 95%CI: 1.20–1.63; $p < 0.001$) and overall survival (HR 1.17; 95%CI: 1.06–1.29; $p = 0.002$)
Dal Pra et al., 2022	Prostate cancer	226 of 350 patients randomised in Swiss Group for Clinical Cancer Research (SAKK) 09/10 trial	22-gene genomic classifier Decipher (Decipher Biosciences Inc) was associated with biochemical progression (HR 2.26; 95%CI: 1.42–3.60; $p < 0.001$), clinical progression (HR 2.29, 95%CI: 1.32–3.98; $p = 0.003$) and use of hormone therapy (sHR 2.99, 95% CI 1.55–5.76; $p = 0.001$). Patients with high and low Decipher scores had 45% and 71% 5-year freedom from biochemical progression, respectively
Wu et al., 2022	Gliomas	1,395 from Chinese Glioma Genome Atlas and Cancer Genome Atlas	12-gene radiosensitivity predictive index (PI12) had better predictive capacity than the traditional WHO classification system (concordance index: 0.842 vs. 0.787; $p \leq 2.2 \times 10^{-16}$)
Sjöström et al., 2023	Breast cancer	729 patients from the SweBCG91-RT trial and Princess Margaret Hospital	A 16-gene signature named Profile for the Omission of Local Adjuvant Radiation (POLAR). POLAR low-risk patients did not benefit from adjuvant RT (HR 1.1; 95% CI 0.39–3.40; $p = 0.81$; HR 1.5; 95% CI 0.14–16, $p = 0.74$). POLAR high-risk patients had a significantly lower risk of locoregional recurrence with RT (HR 0.43; 95% CI 0.24–0.78; $p = 0.006$; HR 0.25; 95%CI 0.07–0.92; $p = 0.038$)
Spratt et al., 2023	Prostate cancer	215 patients from NRG Oncology/RTOG 0126	22-gene genomic classifier Decipher (Decipher Biosciences Inc) was independently prognostic for disease progression (sHR 1.12; 95%CI 1.00–1.26, $p = 0.04$), biochemical failure (sHR 1.22; 95%CI 1.10–1.37, $p < 0.001$), distant metastasis (sHR 1.28; 95%CI 1.06–1.55, $p = 0.01$) and prostate cancer-specific mortality (sHR 1.45; 95%CI 1.20–1.76, $p < 0.001$)

95%CI, 95% confidence interval; HR, hazard ratio; sHR, subdistribution hazard ratio.

(Zhong and Prentice, 2010). The Radiogenomics Consortium remains active, and a significant increase in sample size has led to the discovery of several potentially relevant relationships. An analysis of breast and prostate cancer patients from 17 cohorts indicated that the *ATM* rs1801516 SNP is associated with an increased risk of radiation toxicity (Andreassen et al., 2016). A recent study has revealed a strong association between radiation-induced

mucositis and the rs1131769*C locus in the *STING1* gene on chromosome 5 (Schack et al., 2022).

A definitive answer to the SNVs' role in healthy tissues' response to radiation may come from the international, multicentre REQUITE project (www.requite.eu) funded by the European Union through its 7th Framework Programme (West et al., 2014). The project, performed in collaboration with the

Radiogenomics Consortium, aimed at predicting and reducing the risk of long-term side effects of radiotherapy and completed patient recruitment (Seibold *et al.*, 2019). REQUITE reported that polygenic risk scores (PRS) may be clinically useful and that incorporation of SNP-SNP interactions improves patient classification and prediction of radiotherapy-related toxicity (Franco *et al.*, 2021). This project significantly advanced the collaborations among stakeholders, including healthcare professionals, researchers and industry partners, highlighting the importance of personalised radiotherapy. Other collaborative genetic association studies at both the national and global levels include Gene-PARE (Ho *et al.*, 2006), RadGenomics (Iwakawa *et al.*, 2002) and RAPPER (Burnet *et al.*, 2013). Understanding the impact of radiogenomic heterogeneity on normal tissue radiation toxicity is essential for developing more effective and safe personalised strategies.

In summary, for a long time, radiotherapy optimisation was focused on dosage conformity rather than biological factors. It is critical to factor in tumour heterogeneity when considering radiotherapy outcomes; hence, developing and verifying molecular signatures such as PORTOS, ARTIC and POLAR, together with pan-cancer RSI, constitute the base for resolving this predicament.

Other factors

Circadian heterogeneity

The efficacy of anticancer treatment may also be affected by circadian rhythm, a biological phenomenon displaying endogenous, untrainable 24-h oscillation (Lee, 2021). The circadian clock regulates several key processes in the human body, including metabolism and cell division, with 40% of the transcriptome under circadian control in at least some tissues (Ruben *et al.*, 2018). Recently, a comprehensive analysis of clock genes across different human cancers was performed using primary solid tumour data from The Cancer Genome Atlas (Ye *et al.*, 2018). Based on the available evidence, the International Agency for Research on Cancer classified shift work that involves circadian disruption as potentially carcinogenic to humans (IARC Monographs Vol 124 group, 2019).

Chronotherapy involves administering treatment at specific times of day to optimise its effectiveness and minimise side effects (Zhou *et al.*, 2021). This approach has been tested in several clinical trials with conflicting results: some showed improved efficacy and reduced toxicity (Lévi *et al.*, 1997; Giacchetti *et al.*, 2006), whereas others did not demonstrate significant differences (Garufi *et al.*, 2006; Qvortrup *et al.*, 2010). Some data indicate that chronomodulation might be relevant in the context of immunotherapy. For instance, a recent provocative study reported inferior overall survival in patients who received more than 20% of immunotherapy infusions after 4:30 PM (Qian *et al.*, 2021). However, these observations warrant verification in prospective randomised clinical trials. Data pertinent to radiotherapy comes from the REQUITE project, which disclosed novel serendipitous associations, for example, the interaction between time, circadian rhythm-related genes (*CLOCK*, *PER3* and *RASD1*) and late radiation toxicity in breast cancer patients (Webb *et al.*, 2022).

Microbiome heterogeneity

The human microbiome, comprising trillions of diverse microbial organisms, plays a significant role in modulating health and disease states, including cancer (Hou *et al.*, 2022). Recent research indicates

that microbiome heterogeneity can greatly influence response to anticancer treatment via drug-microbiota interactions.

Bacteria-derived enzymes target chemical compounds, including drugs used in systemic treatment. For example, approximately 40% of patients treated with irinotecan experience severe mucositis, sometimes leading to treatment cessation. Irinotecan is converted into its active form, SN38, which is later reverted back to an inactive form, SN38G, in the liver. Bacterial β -glucuronidases can then convert SN38G in the gastrointestinal tract back to its toxic form (Wallace *et al.*, 2010). Additionally, *Bifidobacterium longum*, *Collinsella aerofaciens* and *Enterococcus faecium* abundance in stool was found to be associated with increased response to anti-PD-1 treatment in patients with melanoma (Matson *et al.*, 2018).

Additionally, the gut microbiome generates numerous metabolites, with short-chain fatty acids (SCFAs) being among the most prevalent and crucial. Significantly, SCFAs act as secondary messengers that facilitate signal transmission and influence the onset and progression of various diseases. Radiotherapy can modify the populations of bacteria that produce SCFAs, leading to changes in SCFA levels, which are linked to several conditions, including radiation-induced intestinal injury (Li *et al.*, 2021).

The microbiome studies shape oncologic outcomes and are now being leveraged for the development of novel personalised therapeutic approaches in anticancer treatment. However, this topic exceeds the scope of this paper and has been addressed elsewhere (Chrysostomou *et al.*, 2023; Yi *et al.*, 2023).

Conclusions

Precision medicine has made remarkable progress in oncology by promising to administer therapy to “the right patient at the right time” (Abrahams, 2008). This review has discussed the impact of cancer heterogeneity as a major challenge facing precision oncology development. Apart from affecting treatment outcomes, heterogeneity can also be employed in the context of prevention and early detection. The results of the first large-scale observational cohort study evaluating methylation-based multicancer early detection diagnostic test (SIMPLIFY) have demonstrated the feasibility of this approach (Rebeck *et al.*, 2018; Nicholson *et al.*, 2023; Tie, 2023).

Genomic makeup has been shown to impact the effectiveness and toxicity of systemic treatments and radiotherapy. Thus, genomic testing can identify pathogenic gene variants and polymorphisms affecting drug metabolism or mechanism of action, thus increasing the risk of treatment failure or toxicity. Spatial and temporal tumoural heterogeneity is a complex phenomenon linked to resistance to therapy, disease progression and adverse prognosis. There are substantial genetic and molecular differences across various tumour regions and between primary and metastatic foci. A better understanding of this phenomenon allowed for the development of novel strategies, for example, targeting with systemic therapies or radiation-specific tumour regions or populations of cancer cells.

Implementing advanced technologies, such as NGS, liquid biopsies and imaging modalities, has fostered precision oncology, accounting for both genomic and tumoural heterogeneity. NGS is routinely used to examine mutations in, for example, *EGFR*, *BRAF* and *ALK*, which are molecular targets for modern therapies. Liquid biopsies, which involve analysing circulating tumour cells or circulating tumour DNA, offer a noninvasive way to identify genetic alterations and monitor tumour progression. Several clinical trials,

including the ongoing NCI-MATCH and MASTER trials and the previously completed MyPathway and MPACT trials, have been designed to identify genetic mutations associated with specific targeted therapies and develop novel treatment strategies for overcoming therapy resistance. These trials are expected to prompt further development of precision oncology.

As precision oncology continues to evolve, the future holds great promise for overcoming current challenges. Advanced tools should be more accessible and affordable. There is a need for routine, more comprehensive genomic profiling of different regions of primary and metastatic tumours to fully understand cancer heterogeneity. In addition, integrating machine learning algorithms and artificial intelligence would allow better identification of new therapeutic targets and the development of even more personalised treatment strategies. An exciting area of future research in precision oncology is the use of combination therapies that simultaneously target multiple pathways and molecular targets; this approach has the potential to overcome heterogeneity-led resistance to single-agent targeted therapies. Another area for improvement is integrating precision oncology into clinical practice and expanding access to new technologies for community oncologists and patients. This will require the development of user-friendly platforms and tools that are easily integrable into clinical workflows.

Overall, precision oncology holds great promise for improving cancer treatment efficacy by enabling personalised treatment strategies based on unique cancer and patient characteristics. Although challenges remain to be addressed, ongoing research and emerging developments create real hope for breath-taking therapeutic approaches and improved patient outcomes.

Open peer review. To view the open peer review materials for this article, please visit <http://doi.org/10.1017/pcm.2023.23>.

Author contribution. J.J. and B.T. developed the paper concept and outline. B.T., F.G., M.Br. and M.Bi. collected and assembled the data. J.J. provided administrative support and oversight and revised the text. F.G. prepared the figures. B.T., F.G., M.Br., M.Bi. and J.J. wrote and approved the manuscript. B.T. and F.G. contributed equally to this work.

Financial support. F.G. is supported by Polish National Science Centre Grants PRELUDIUM 2018/31/N/NZ5/03214, ETIUDA 2020/36/T/NZ5/00610, and Polish Stem Cells Bank grant ExCELLent.

Competing interest. J.J. declares advisory roles for BMS, Roche and MSD, lectures for Roche (not compensated), Pfizer, Novartis and MSD and travel support from Takeda. Other authors have no conflicts of interest to declare.

References

- Aggarwal C, Davis CW, Mick R, Thompson JC, Ahmed S, Jeffries S, Bagley S, Gabriel P, Evans TL, Bauml JM, Ciunci C, Alley E, Morrisette JJD, Cohen RB, Carpenter EL and Langer CJ (2018) Influence of TP53 mutation on survival in patients with advanced EGFR-mutant non-small-cell lung cancer. *JCO Precision Oncology* **2018**, PO.18.00107.
- Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD and GBM AGILE Network (2018) Adaptive global innovative learning environment for glioblastoma: GBM AGILE. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* **24**, 737–743.
- Alfonso JCL and Berk L (2019) Modeling the effect of intratumoral heterogeneity of radiosensitivity on tumor response over the course of fractionated radiation therapy. *Radiation Oncology (London, England)* **14**, 88.
- Almendo V, Cheng Y-K, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale A-L, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F and Polyak K (2014) Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. *Cell Reports* **6**, 514–527.
- Amstutz U, Farese S, Aebi S and Largiadèr CR (2009) Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: A haplotype assessment. *Pharmacogenomics* **10**, 931–944.
- Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, Sablin M-P, Campone M, Bonnefoi H, Lefeuvre-Plesse C, Jacot W, Coussy F, Ferrero J-M, Emile G, Mouret-Reynier M-A, Thery J-C, Isambert N, Mege A, Barthelemy P, You B, Hajjaji N, Lacroix L, Rouleau E, Tran-Dien A, Boyault S, Attignon V, Gestraud P, Servant N, Le Tourneau C, Cherif LL, Soubeyran I, Montemurro F, Morel A, Lusque A, Jimenez M, Jacquet A, Gonçalves A, Bachelot T and Bieche I (2022) Genomics to select treatment for patients with metastatic breast cancer. *Nature* **610**, 343–348.
- Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruyscher D, Cesarotti JA, Barnett GC, Dunning AM, Dorling L, West CML, Burnet NG, Elliott R, Coles C, Hall E, Fachal L, Vega A, Gómez-Caamaño A, Talbot CJ, Symonds RP, De Ruyck K, Thierens H, Ost P, Chang-Claude J, Seibold P, Popanda O, Overgaard M, Dearnaley D, Sydes MR, Azria D, Koch CA, Parliament M, Blackshaw M, Sia M, Fuentes-Raspall MJ, Cajal TR, Barnadas A, Vesprini D, Gutiérrez-Enríquez S, Mollá M, Díez O, Yarnold JR, Overgaard J, Bentzen SM and Alsner J (2016) Individual patient data meta-analysis shows a significant association between the ATM Rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. *Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology* **121**, 431–439.
- Andreassen CN, Schack LMH, Laursen LV and Alsner J (2016) Radiogenomics – Current status, challenges and future directions. *Cancer Letters* **382**, 127–136.
- Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, Mitchell EP, Zwiebel JA, Sharon E, Streicher H, Li S, McShane LM, Rubinstein L, Patton DR, Williams PM, Coffey B, Hamilton SR, Bahary N, Suga JM, Hatoum H, Abrams JS, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Chen AP and Flaherty KT (2020) Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: Results from arm Z1D—A subprotocol of the NCI-MATCH (EAY131) study. *Journal of Clinical Oncology* **38**, 214–222.
- Babina IS and Turner NC (2017) Advances and challenges in targeting FGFR Signalling in cancer. *Nature Reviews. Cancer* **17**, 318–332.
- Bachelot T, Filleron T, Bieche I, Arnedos M, Campone M, Dalenc F, Coussy F, Sablin M-P, Debled M, Lefeuvre-Plesse C, Goncalves A, Reynier M-AM, Jacot W, You B, Barthelemy P, Verret B, Isambert N, Tchiknavorian X, Levy C, Thery J-C, L'Haridon T, Ferrero J-M, Mege A, Del Piano F, Rouleau E, Tran-Dien A, Adam J, Lusque A, Jimenez M, Jacquet A, Garberis I and Andre F (2021) Durvalumab compared to maintenance chemotherapy in metastatic BREAST cancer: The randomized phase II SAFIR02-BREAST IMMUNO trial. *Nature Medicine* **27**, 250–255.
- Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, Wilkinson JS, Tyrer J, Misra V, Platte R, Gulliford SL, Sydes MR, Hall E, Bentzen SM, Dearnaley DP, Burnet NG, Pharoah PDP, Dunning AM and West CML (2012) Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: A prospective analysis study. *The Lancet. Oncology* **13**, 65–77.
- Barnett GC, West CML, Dunning AM, Elliott RM, Coles CE, Pharoah PDP and Burnet NG (2009) Normal tissue reactions to radiotherapy: Towards tailoring treatment dose by genotype. *Nature Reviews. Cancer* **9**, 134–142.
- Bedard PL, Li S, Wisinski KB, Yang ES, Limaye SA, Mitchell EP, Zwiebel JA, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP and Flaherty KT (2022) Phase II study of Afatinib in patients with tumors with human epidermal growth factor receptor 2-activating mutations: Results from the National Cancer Institute–molecular analysis for therapy choice ECOG-ACRIN trial (EAY131) subprotocol EAY131-B. *JCO Precision Oncology* **6**, e2200165.
- Bentzen SM (2006) Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. *Nature Reviews. Cancer* **6**, 702–713.

- Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN and Woodward WA (2019) The implications of genetic testing on radiation therapy decisions: A guide for radiation oncologists. *International Journal of Radiation Oncology, Biology, Physics* 105, 698–712.
- Bertilsson L, Dahl M-L, Dalén P and Al-Shurbaji A (2002) Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. *British Journal of Clinical Pharmacology* 53, 111–122.
- Bin Lim S, Chua MLK, Yeong JPS, Tan SJ, Lim W-T and Lim CT (2019) Pan-Cancer analysis connects tumor Matrisome to immune response. *npj Precision Oncology* 3, 15.
- Binkley MS, Jeon Y-J, Nesselbush M, Moding EJ, Nabet BY, Almanza D, Kunder C, Stehr H, Yoo CH, Rhee S, Xiang M, Chabon JJ, Hamilton E, Kurtz DM, Gojenola L, Owen SG, Ko RB, Shin JH, Maxim PG, Lui NS, Backhus LM, Berry MF, Shrager JB, Ramchandran KJ, Padma SK, Das M, Neal JW, Wakelee HA, Alizadeh AA, Loo BW and Diehn M (2020) KEAP1/NFE2L2 mutations predict lung Cancer radiation resistance that can be targeted by glutaminase inhibition. *Cancer Discovery* 10, 1826–1841.
- Blackstone EH (2019) Precision medicine versus evidence-based medicine: Individual treatment effect versus average treatment effect. *Circulation* 140, 1236–1238.
- Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER and Ellis MJ (2013) Activating HER2 mutations in HER2 gene amplification negative breast Cancer. *Cancer Discovery* 3, 224–237.
- Brown LC, Graham J, Fisher D, Adams R, Seligmann J, Seymour M, Kaplan R, Yates E, Parmar M, Richman SD, Quirke P, Butler R, Shiu K, Middleton G, Samuel L, Wilson RH and Maughan TS (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal Cancer. *Clinical Trials (London, England)* 19, 146–157.
- Burnet NG, Barnett GC, Elliott RM, Dearnaley DP, Pharoah PDP, Dunning AM, West CML and RAPPER Investigators (2013) RAPPER: The radio-genomics of radiation toxicity. *Clinical Oncology (Royal College of Radiologists (Great Britain))* 25, 431–434.
- Burrell RA, McGranahan N, Bartek J and Swanton C (2013) The causes and consequences of genetic heterogeneity in cancer evolution. *Nature* 501, 338–345.
- Cagney DN, Sul J, Huang RY, Ligon KL, Wen PY and Alexander BM (2018) The FDA NIH biomarkers, EndpointS, and other tools (BEST) resource in neuro-oncology. *Neuro-Oncology* 20, 1162–1172.
- Califf RM (2018) Biomarker definitions and their applications. *Experimental Biology and Medicine (Maywood, N.J.)* 243, 213–221.
- Casey DL, Pitter KL, Wexler LH, Slotkin EK, Gupta GP and Wolden SL (2021) TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma. *British Journal of Cancer* 125, 576–581.
- Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA and Diaz LA (2022) PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. *The New England Journal of Medicine* 386, 2363–2376.
- Cerchione C, Romano A, Daver N, DiNardo C, Jabbour EJ, Konopleva M, Ravandi-Kashani F, Kadia T, Martelli MP, Isidori A, Martinelli G and Kantarjian H (2021) IDH1/IDH2 inhibition in acute myeloid leukemia. *Frontiers in Oncology* 11, 639387.
- Chabner BA and Roberts TG (2005) Timeline: Chemotherapy and the war on cancer. *Nature Reviews. Cancer* 5, 65–72.
- Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP and Flaherty KT (2020) Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: Results from the NCI-MATCH trial (EAY131) subprotocol W. *Journal of Clinical Oncology* 38, 2407–2417.
- Chen R and Snyder M (2013) Promise of personalized omics to precision medicine. *Wiley Interdisciplinary Reviews. Systems Biology and Medicine* 5, 73–82.
- Chi SN, Yi JS, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Mhlanga J, Fox E, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel N and Parsons DW (2022) Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG pediatric MATCH trial arm C (APEC1621C). *Journal of Clinical Oncology* 40, 10009–10009.
- Chrysostomou D, Roberts LA, Marchesi JR and Kinross JM (2023) Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy. *Gastroenterology* 164, 198–213.
- Citrin DE (2017) Recent developments in radiotherapy. *The New England Journal of Medicine* 377, 1065–1075.
- Clark AS, Hong F, Finn RS, DeMichele AM, Mitchell EP, Zwiebel J, Arnaldez FI, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Copur MS, Kasbari SS, Thind R, Conley BA, Arteaga CL, O'Dwyer PJ, Harris LN, Chen AP and Flaherty KT (2023) Phase II study of palbociclib (PD-0332991) in CCND1, 2, or 3 amplification: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1B. *Clinical Cancer Research* 29, OF1–OF7.
- Cleary JM, Wang V, Heist RS, Kopetz ES, Mitchell EP, Zwiebel JA, Kapner KS, Chen HX, Li S, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Meric-Bernstam F, Dillmon MS, Williams PM, Hamilton SR, Conley BA, Aguirre AJ, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP and Flaherty KT (2021) Differential outcomes in codon 12/13 and codon 61 NRAS-mutated cancers in the phase II NCI-MATCH trial of binimetinib in patients with NRAS-mutated tumors. *Clinical Cancer Research* 27, 2996–3004.
- Collins FS and Varmus H (2015) A new initiative on precision medicine. *The New England Journal of Medicine* 372, 793–795.
- Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC and Clinical Pharmacogenetics Implementation Consortium (2014) Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. *Clinical Pharmacology and Therapeutics* 95, 376–382.
- Cristofanilli M, Rugo HS, Im S-A, Slamon DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O'Leary B, André F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Freaun MJ and Turner NC (2022) Overall survival with palbociclib and fulvestrant in women with HR+/HER2– ABC: Updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* 28, 3433–3442.
- Cui Y, Li B, Pollom EL, Horst KC and Li R (2018) Integrating radiosensitivity and immune gene signatures for predicting benefit of radiotherapy in breast Cancer. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* 24, 4754–4762.
- Custodio AB, González-Larriba JL, Bobokova J, Calles A, Alvarez R, Cuadrado E, Manzano A and Díaz-Rubio E (2009) Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung Cancer. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer* 4, 891–910.
- Dagogo-Jack I and Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. *Nature Reviews. Clinical Oncology* 15, 81–94.
- Dai Y-H, Wang Y-F, Shen P-C, Lo C-H, Yang J-F, Lin C-S, Chao H-L and Huang W-Y (2021) Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy. *NPJ Genomic Medicine* 6, 40.
- Dal Pra A, Ghadjar P, Hayoz S, Liu VYT, Spratt DE, Thompson DJS, Davicioni E, Huang H-C, Zhao X, Liu Y, Schär C, Gut P, Plasswilm L, Hölscher T, Polat B, Hildebrandt G, Müller A-C, Pollack A, Thalmann GN, Zwahlen D and Aebersold DM (2022) Validation of the decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial. *Annals of Oncology: Official Journal of the European Society for Medical Oncology* 33, 950–958.
- Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Suga JM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP and Flaherty KT (2022) Phase II study of Copanlisib in patients with tumors with PIK3CA mutations: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1F. *Journal of Clinical Oncology* 40, 1552–1561.

- de Bono JS and Ashworth A (2010) Translating cancer research into targeted therapeutics. *Nature* **467**, 543–549.
- Dickson D, Johnson J, Bergan R, Owens R, Subbiah V and Kurzrock R (2020) The master observational trial: A new class of master protocol to advance precision medicine. *Cell* **180**, 9–14.
- Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD and Trial investigators (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials. *The Lancet. Oncology* **21**, 271–282.
- Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocáková I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R and Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal Cancer. *New England Journal of Medicine* **369**, 1023–1034.
- Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn M-J, Wolf J, Seto T, Cho BC, Patel MR, Chiu C-H, John T, Goto K, Karapetis CS, Arkenau H-T, Kim S-W, Ohe Y, Li Y-C, Chae YK, Chung CH, Otterson GA, Murakami H, Lin C-C, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC and trial investigators (2020) Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1-2 trials. *The Lancet. Oncology* **21**, 261–270.
- Eckstein OS, Allen CE, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Jaju A, Mhlanga J, Fox E, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL and Parsons DW (2022) Phase II study of selumetinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway genetic alterations: Arm E of the NCI-COG pediatric MATCH trial. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* **40**, 2235–2245.
- Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee J-H, Bloom G, Rocha-Lima C, Kelley S, Calvin DP, Yeatman TJ, Begg AC and Torres-Roca JF (2009) A gene expression model of intrinsic tumor radiosensitivity: Prediction of response and prognosis after chemoradiation. *International Journal of Radiation Oncology, Biology, Physics* **75**, 489–496.
- Fachal L, Gómez-Caamaño A, Barnett GC, Peleteiro P, Carballo AM, Calvo-Crespo P, Kerns SL, Sánchez-García M, Lobato-Busto R, Dorling L, Elliott RM, Dearnaley DP, Sydes MR, Hall E, Burnet NG, Carracedo Á, Rosenstein BS, West CML, Dunning AM and Vega A (2014) A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. *Nature Genetics* **46**, 891–894.
- Feng FY, Huang H-C, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Bahary J-P, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU and Tran PT (2021) Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: An ancillary study of the NRG/TOG 9601 randomized clinical trial. *JAMA Oncology* **7**, 544–552.
- Fernández-Mateos J, Seijas-Tamayo R, Mesía R, Taberna M, Pastor Borgonón M, Pérez-Ruiz E, Adansa Klain JC, Vázquez Fernández S, Del Barco Morillo E, Lozano A, González Sarmiento R, Cruz-Hernández JJ and Spanish Head and Neck Cancer Cooperative Group (TTCC) (2016) Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. *Oral Oncology* **63**, 38–43.
- Flaherty Keith T, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffey B, Fu T, Roubort M, Zwiebel JA, Rubinstein LV, Little RF, Arteaga CL, Comis R, Abrams JS, O'Dwyer PJ, Conley BA and NCI-MATCH Team (2020) Molecular landscape and actionable alterations in a Genomically guided Cancer clinical trial: National Cancer Institute molecular analysis for therapy choice (NCI-MATCH). *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* **38**, 3883–3894.
- Flaherty Keith T, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Roubort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnost R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih C-J, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA and for the NCI-MATCH Team (2020) The molecular analysis for therapy choice (NCI-MATCH) trial: Lessons for genomic trial design. *JNCI: Journal of the National Cancer Institute* **112**, 1021–1029.
- Franco NR, Massi MC, Ieva F, Manzoni A, Paganoni AM, Zunino P, Veldeman L, Ost P, Fonteyne V, Talbot CJ, Rattay T, Webb A, Johnson K, Lambrecht M, Haustermans K, De Meerleer G, de Ruyscher D, Vanneste B, Van Limbergen E, Choudhury A, Elliott RM, Sperk E, Veldwijk MR, Herskind C, Avuzzi B, Noris Chiorda B, Valdagni R, Azria D, Farcy-Jacquet MP, Brengues M, Rosenstein BS, Stock RG, Vega A, Aguado-Barrera ME, Sosa-Fajardo P, Dunning AM, Fachal L, Kerns SL, Payne D, Chang-Claude J, Seibold P, West CML, Rancati T and REQUITE Consortium Collaborators (2021) Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. *Radiotherapy and Oncology* **159**, 241–248.
- Friedman CF, Hainsworth JD, Kurzrock R, Spigel DR, Burris HA, Sweeney CJ, Meric-Bernstam F, Wang Y, Levy J, Grindheim J, Shames DS, Schulze K, Patel A and Swanton C (2022) Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study. *Cancer Discovery* **12**, 654–669.
- Gaborit N, Larbouret C, Vallaghe J, Peyrusson F, Bascoul-Mollevis C, Crapez E, Azria D, Chardès T, Poul M-A, Mathis G, Bazin H and Pèlerin A (2011) Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: A new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. *The Journal of Biological Chemistry* **286**, 11337–11345.
- Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M and Klein TE (2018) The Pharmacogene variation (PharmVar) consortium: Incorporation of the human cytochrome P450 (CYP) allele nomenclature database. *Clinical Pharmacology and Therapeutics* **103**, 399–401.
- Garufi C, Vanni B, Aschelter AM, Zappalà AR, Brià E, Nisticò C, Sperduti I, Cognetti F and Terzoli E (2006) Randomised phase II study of standard versus Chronomodulated CPT-11 plus Chronomodulated 5-fluorouracil and Folinic acid in advanced colorectal Cancer patients. *European Journal of Cancer (Oxford, England: 1990)* **42**, 608–616.
- Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz M-A, Baron B, Gorlia T, Lévi F and European Organisation for Research and Treatment of Cancer Chronotherapy Group (2006) Phase III trial comparing 4-Day chronomodulated therapy versus 2-Day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal Cancer: The European Organisation for Research and Treatment of Cancer chronotherapy group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* **24**, 3562–3569.
- Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinsilboum RM, Ames MM and Ingle JN (2013) CYP2D6 metabolism and patient outcome in the Austrian breast and colorectal Cancer study group trial (ABCSCG) 8. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* **19**, 500–507.
- Gouda MA and Subbiah V (2023) Expanding the benefit: Dabrafenib/Trametinib as tissue-agnostic therapy for BRAF V600E-positive adult and pediatric solid tumors. *American Society of Clinical Oncology Educational Book* **43**, e404770.
- Grass GD, Alfonso JCL, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Enderling H and Torres-Roca JF (2022) The Radiosensitivity index gene signature identifies distinct tumor immune microenvironment characteristics associated with

- susceptibility to radiation therapy. *International Journal of Radiation Oncology, Biology, Physics* 113, 635–647.
- Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V, Bissoni R, Torresi U, Floriani I, Schiavon G, Andreoni F, Maltese P, Rulli E, Humar B, Falcone A, Giustini L, Tonini G, Fontana A, Masi G and Magnani M (2008) Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 26, 1427–1434.
- Greaves M and Maley CC (2012) Clonal evolution in cancer. *Nature* 481, 306–313.
- Guan L, Nambiar DK, Cao H, Viswanathan V, Kwok S, Hui AB, Hou Y, Hildebrand R, von Eyben R, Holmes BJ, Zhao J, Kong CS, Wamsley N, Zhang W, Major MB, Seol SW, Sunwoo JB, Hayes DN, Diehn M and Le Q-T (2023) NFE2L2 mutations enhance radioresistance in head and neck cancer by modulating intratumoral myeloid cells. *Cancer Research* 83, 861–874.
- Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C and Arteaga CL (2017) HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* 23, 4323–4334.
- Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers G-J, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven E van, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar H-J and Schellens JHM (2018) DPYD genotype-guided dose individualisation of Fluoropyrimidine therapy in patients with Cancer: A prospective safety analysis. *The Lancet. Oncology* 19, 1459–1467.
- Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, Green S, Haffty B, Drumea K, Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J, Andreassen CN, Trop CS, Park J and Rosenstein BS (2006) Genetic predictors of adverse radiotherapy effects: The gene-PARE project. *International Journal of Radiation Oncology, Biology, Physics* 65, 646–655.
- Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, van der Velden DL, van de Haar J, Roepman P, de Leng WJ, Jansen AML, van Werkhoven E, van der Noort V, Huitema ADR, Gort EH, de Groot JWB, Kerver ED, de Groot DJ, Erdkamp F, Beerepoot LV, Hendriks MP, Smit EF, van der Graaf WTA, van Herpen CML, Labots M, Hoeben A, Morreau H, Lolkema MP, Cuppen E, Gelderblom H, Verheul HMW and Voest EE (2022) Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment. *Clinical Cancer Research* 28, 1402–1411.
- Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hüllein J, Fröhlich M, Uhrig S, Jahn A, Rump A, Gieldon L, Möhrmann L, Hanf D, Teleanu V, Heilig CE, Lipka DB, Allgäuer M, Ruhnke L, Laßmann A, Endris V, Neumann O, Penzel R, Beck K, Richter D, Winter U, Wolf S, Pfütze K, Georg C, Meißburger B, Buchhalter I, Augustin M, Aulitzky WE, Hohenberger P, Kroiss M, Schirmacher P, Schlenk RF, Keilholz U, Klauschen F, Folprecht G, Bauer S, Sivek JT, Brandts CH, Kindler T, Boerries M, Illert AL, von Bubnoff N, Jost PJ, Spiekermann K, Bitzer M, Schulze-Osthoff K, von Kalle C, Klink B, Brors B, Stenzinger A, Schröck E, Hübschmann D, Weichert W, Glimm H and Fröhling S (2021) Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. *Cancer Discovery* 11, 2780–2795.
- Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Georg C, Meißburger B, Wolf S, Schulz A, Penzel R, Herpel E, Kirchner M, Lier A, Endris V, Singer S, Schirmacher P, Weichert W, Stenzinger A, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H and Fröhling S (2017) Precision oncology based on omics data: The NCT Heidelberg experience. *International Journal of Cancer* 141, 877–886.
- Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J and Chen ZS (2022) Microbiota in health and diseases. *Signal Transduction and Targeted Therapy* 7, 1–28.
- Huang R-X and Zhou P-K (2020) DNA damage response signaling pathways and targets for radiotherapy sensitization in Cancer. *Signal Transduction and Targeted Therapy* 5, 60.
- Hutchinson M-KND, Mierzwa M and D'Silva NJ (2020) Radiation resistance in head and neck squamous cell carcinoma: Dire need for an appropriate sensitizer. *Oncogene* 39, 3638–3649.
- IARC Monographs Vol 124 group (2019) Carcinogenicity of night shift work. *The Lancet. Oncology* 20, 1058–1059.
- Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. *Trends in Pharmacological Sciences* 25, 193–200.
- Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE and Ratain MJ (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 22, 1382–1388.
- Iwakawa M, Imai T, Harada Y, Ban S, Michikawa Y, Saegusa K, Sagara M, Tsuji A, Noda S and Ishikawa A (2002) (RadGenomics project). *Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica* 62, 484–489.
- Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL and Ratain MJ (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. *The Pharmacogenomics Journal* 2, 43–47.
- Jameel JKA, Rao VSR, Cawkwell L and Drew PJ (2004) Radioresistance in carcinoma of the breast. *Breast (Edinburgh, Scotland)* 13, 452–460.
- Jameson JL and Longo DL (2015) Precision medicine — Personalized, problematic, and promising. *New England Journal of Medicine* 372, 2229–2234.
- Jee J, Lebow ES, Yeh R, Das JP, Namakydoust A, Paik PK, Chaff J, Jayakumar G, Rose Brannon A, Benayed R, Zehir A, Donoghue M, Schultz N, Chakravarty D, Kundra R, Madupuri R, Murciano-Goroff YR, Tu HY, Xu CR, Martinez A, Wilhelm C, Galle J, Daly B, Yu HA, Offin M, Hellmann MD, Lito P, Arbour KC, Zauderer MG, Kris MG, Ng KK, Eng J, Preeshagul I, Victoria Lai W, Fiore JJ, Iqbal A, Molena D, Rocco G, Park BJ, Lim LP, Li M, Tong-Li C, De Silva M, Chan DL, Diakos CI, Itchins M, Clarke S, Pavlakis N, Lee A, Rektman N, Chang J, Travis WD, Riely GJ, Solit DB, Gonen M, Rusch VW, Rimmer A, Gomez D, Drilon A, Scher HI, Shah SP, Berger MF, Arcila ME, Ladanyi M, Levine RL, Shen R, Razavi P, Reis-Filho JS, Jones DR, Rudin CM, Isbell JM, Li BT (2022) Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. *Nature Medicine* 28, 2353–2363.
- Johnson DB, Zhao F, Noel M, Riely GJ, Mitchell EP, Wright JJ, Chen HX, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP and Flaherty KT (2020) Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: Results from NCI-MATCH (EAY131). *Clinical Cancer Research* 26, 1812–1819.
- Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, Doyle LA, McShane LM, Li S, Gray RJ, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP and Flaherty KT (2021) Effect of Capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial. *JAMA Oncology* 7, 271–278.
- Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O'Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME, Neale BM, Daly MJ and MacArthur DG (2020) The mutational constraint Spectrum quantified from variation in 141,456 humans. *Nature* 581, 434–443.
- Khoury JD, Wang W-L, Prieto VG, Medeiros LJ, Kalhor N, Hameed M, Broaddus R and Hamilton SR (2018) Validation of immunohistochemical

- assays for integral biomarkers in the NCI-MATCH EAY131 clinical trial. *Clinical Cancer Research* 24, 521–531.
- Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM and Hong WK** (2011) The BATTLE trial: Personalizing therapy for lung Cancer. *Cancer Discovery* 1, 44–53.
- Kim SI, Kang JW, Noh JK, Jung HR, Lee YC, Lee JW, Kong M and Eun Y-G** (2020) Gene signature for prediction of radiosensitivity in human papillomavirus-negative head and neck squamous cell carcinoma. *Radiation Oncology Journal* 38, 99–108.
- Klinghammer K, Knödler M, Schmittl A, Budach V, Keilholz U and Tinhofer I** (2010) Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* 16, 304–310.
- Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA and Gynecologic Oncology Group Phase III Trial** (2008) Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian Cancer. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 26, 3598–3606.
- Krop IE, Jegede OA, Grilley-Olson JE, Lauring JD, Mitchell EP, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Kono SA, Ford JM, Garcia AA, Sui XD, Siegel RD, Slomovitz BM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP and Flaherty KT** (2022) Phase II study of Taselisib in PIK3CA-mutated solid tumors other than breast and squamous lung Cancer: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol I. *JCO Precision Oncology* 6, e2100424.
- Labrie M, Brugge JS, Mills GB and Zervantonakis IK** (2022) Therapy resistance: Opportunities created by adaptive responses to targeted therapies in cancer. *Nature Reviews. Cancer* 22, 323–339.
- Lauschke VM, Milani L and Ingelman-Sundberg M** (2017) Pharmacogenomic biomarkers for improved drug therapy—Recent Progress and future developments. *The AAPS Journal* 20, 4.
- Le Tourneau C, Delord JP, Delord J-P, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Tredan O, Trédan O vier, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jézéquel P, Pascal Jézéquel, Valéry Attignon, Attignon V, Boyault S, Boyault S, Vincent-Salomon A, Servois V, Sablin M-P, Sablin MP, Kamal M and Paoletti X** (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced Cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. *Lancet Oncology* 16, 1324–1334.
- Lee Y** (2021) Roles of circadian clocks in Cancer pathogenesis and treatment. *Experimental & Molecular Medicine* 53, 1529–1538.
- Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar A-L, Neumann O, Kirchner M, Ploeger C, Budczies J, Heilig CE, Hutter B, Fröhlich M, Uhrig S, Kazdal D, Allgäuer M, Harms A, Rempel E, Lehmann U, Thomas M, Pfarr N, Azoitel N, Bonzheim I, Marienfeld R, Möller P, Werner M, Fend F, Boerries M, von Bubnoff N, Lassmann S, Longerich T, Bitzer M, Seufferlein T, Malek N, Weichert W, Schirmacher P, Penzel R, Endris V, Brors B, Klauschen F, Glimm H, Fröhling S and Stenzinger A** (2019) Variant classification in precision oncology. *International Journal of Cancer* 145, 2996–3010.
- Lévi F, Zidani R and Misset JL** (1997) Randomised multicentre trial of chronotherapy with Oxaliplatin, fluorouracil, and Folinic acid in metastatic colorectal Cancer. *International Organization for Cancer Chronotherapy. Lancet (London, England)* 350, 681–686.
- Li Y, Zhang Y, Wei K, He J, Ding N, Hua J, Zhou T, Niu F, Zhou G, Shi T, Zhang L and Liu Y** (2021) Review: Effect of Gut microbiota and its metabolite SCFAs on radiation-induced intestinal injury. *Frontiers in Cellular and Infection Microbiology* 11:577236.
- Lih C-J, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafate AJ, Sklar JL, Hamilton SR and Williams PM** (2017) Analytical validation of the next-generation sequencing assay for a Nationwide signal-finding clinical trial: Molecular analysis for therapy choice clinical trial. *The Journal of Molecular Diagnostics* 19, 313–327.
- Lim H-S, Ju Lee H, Seok Lee K, Sook Lee E, Jang I-J and Ro J** (2007) Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast Cancer. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 25, 3837–3845.
- Mangata PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, Stella PJ, Voest E, Yost KJ, Perlmutter J, Pinto N, Kim ES and Schilsky RL** (2018) Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) study. *JCO Precision Oncology* 2018, 1–14. <https://doi.org/10.1200/PO.18.00122>.
- Mansfield AS, Wei Z, Mehra R, Shaw AT, Lieu CH, Forde PM, Drilon AE, Mitchell EP, Wright JJ, Takebe N, Sharon E, Hovelson D, Tomlins S, Zeng J, Poorman K, Malik N, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP and Flaherty KT** (2022) Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. *NPJ Precision Oncology* 6, 1–6.
- Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M and Baiget M** (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal Cancer. *British Journal of Cancer* 91, 678–682.
- Massard C, Michiels S, Féré C, Le Deley M-C, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec J-Y, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F and Soria J-C** (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial. *Cancer Discovery* 7, 586–595.
- Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS and Wistuba II** (2007) KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung Cancer. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* 13, 2890–2896.
- Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ and Gajewski TF** (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science (New York, N.Y.)* 359, 104–108.
- Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J and Gautschi O** (2019) Immune checkpoint inhibitors for patients with advanced lung Cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry. *Annals of Oncology* 30, 1321–1328.
- McGranahan N and Swanton C** (2017) Clonal heterogeneity and tumor evolution: Past, present, and the future. *Cell* 168, 613–628.
- Mirnezami R, Nicholson J and Darzi A** (2012) Preparing for precision medicine. *New England Journal of Medicine* 366, 489–491.
- Mistry HB** (2023) Radiosensitivity index is not fit to be used for dose adjustments: A pan-cancer analysis. *Clinical Oncology (Royal College of Radiologists (Great Britain))* 35, 565–570.
- Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, Le Tourneau C, Sablin M-P, Lacroix L, Enrico D, Miran I, Jovelet C, Bièche I, Soria J-C, Bertucci F, Bonnefoi H, Campone M, Dalenc F, Bachelot T, Jacquet A, Jimenez M and André F** (2020) Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. *Annals of Oncology: Official Journal of the European Society for Medical Oncology* 31, 377–386.
- Munro AJ, Lain S and Lane DP** (2005) P53 abnormalities and outcomes in colorectal cancer: A systematic review. *British Journal of Cancer* 92, 434–444.

- Nath A and Bild AH (2021) Leveraging single-cell approaches in cancer precision medicine. *Trends in Cancer* 7, 359–372.
- Nicholson BD, Oke J, Virdee PS, Harris DA, O'Doherty C, Park JE, Hamady Z, Sehgal V, Millar A, Medley L, Tonner S, Vargova M, Engonidou L, Riahi K, Luan Y, Hiom S, Kumar H, Nandani H, Kurtzman KN, Yu LM, Freestone C, Pearson S, Hobbs FR, Perera R and Middleton MR (2023) Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLOY): A large-scale, observational cohort study. *The Lancet Oncology* 24, 733–743.
- Ning B, Liu Y, Wang M, Li Y, Xu T and Wei Y (2022) The predictive value of tumor mutation burden on clinical efficacy of immune checkpoint inhibitors in melanoma: A systematic review and meta-analysis. *Frontiers in Pharmacology* 13, 748674.
- O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH, Safra T, Italiano A, Mileskin L, Xu L, Jin F, Norwood K and Maio M (2022) Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: Results from the KEYNOTE-158 study. *Journal of Clinical Oncology* 40, 752–761.
- Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL and Diasio RB (2014) Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. *Cancer Research* 74, 2545–2554.
- Oike Tae, Sekiguchi Y, Yoshimoto Y, Oike Takahiro, Ando K, Gu W, Sasaki Y, Tokino T, Iwase A and Ohno T (2021) Mutation analysis of radioresistant early-stage cervical cancer. *International Journal of Molecular Sciences* 23, 51.
- Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S and Lenz HJ (2001) A Xeroderma Pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal Cancer. *Cancer Research* 61, 8654–8658.
- Parker G, Hunter S, Ghazi S, Hayeems RZ, Rousseau F and Miller FA (2023) Decision impact studies, evidence of clinical utility for genomic assays in Cancer: A scoping review. *PLoS One* 18, e0280582.
- Parsons DW, Janeway KA, Patton DR, Winter CL, Coffey B, Williams PM, Roy-Chowdhuri S, Tsongalis GJ, Routbort M, Ramirez NC, Saguilig L, Piao J, Alonzo TA, Berg SL, Fox E, Hawkins DS, Abrams JS, Mooney M, Takebe N, Tricoli JV, Seibel NL and Team the N-CPM (2022) Actionable tumor alterations and treatment protocol enrollment of pediatric and young adult patients with refractory cancers in the National Cancer Institute–Children's oncology group pediatric MATCH trial. *Journal of Clinical Oncology*.
- Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King M-C and Swisher EM (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* 20, 764–775.
- Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S and Licitra L (2010) TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected Oral cavity squamous cell carcinoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 28, 761–766.
- Piasecka D, Braun M, Kitowska K, Mieczkowski K, Kordek R, Sadej R and Romanska H (2019) FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors – Implications for therapy of luminal breast cancer. *Journal of Experimental & Clinical Cancer Research: CR* 38, 230.
- Prasad V, Fojo T and Brada M (2016) Precision oncology: Origins, optimism, and potential. *The Lancet. Oncology* 17, e81–e86.
- Price JM, Prabhakaran A and West CML (2023) Predicting tumour radio-sensitivity to deliver precision radiotherapy. *Nature Reviews. Clinical Oncology* 20, 83–98.
- Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, Zhong J, Yushak ML, Harvey RD, Paulos CM, Lawson DH, Khan MK, Kudchadkar RR and Buchwald ZS (2021) Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): A propensity score-matched analysis of a single-Centre, longitudinal study. *The Lancet. Oncology* 22, 1777–1786.
- Qvortrup C, Jensen BV, Fokstuen T, Nielsen SE, Keldsen N, Glimelius B, Bjerregaard B, Mejer J, Larsen FO and Pfeiffer P (2010) A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. *Annals of Oncology: Official Journal of the European Society for Medical Oncology* 21, 87–91.
- Ramón Y, Cajal S, Sesé M, Capdevila C, Aasen T, De Mattos-Arruda L, Diaz-Cano SJ, Hernández-Losa J and Castellví J (2020) Clinical implications of Intratumor heterogeneity: Challenges and opportunities. *Journal of Molecular Medicine (Berlin, Germany)* 98, 161–177.
- Rebbeck TR, Burns-White K, Chan AT, Emmons K, Freedman M, Hunter DJ, Kraft P, Laden F, Mucci L, Parmigiani G, Schrag D, Syngal S, Tamimi RM, Viswanath K, Yurgelun MB and Garber JE (2018) Precision prevention and early detection of cancer: Fundamental principles. *Cancer Discovery* 8, 803–811.
- Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leigh N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR and Herbst RS (2020) Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (lung-MAP SWOG S1400): A biomarker-driven master protocol. *The Lancet. Oncology* 21, 1589–1601.
- Reisz JA, Bansal N, Qian J, Zhao W and Furdul CM (2014) Effects of ionizing radiation on biological molecules—Mechanisms of damage and emerging methods of detection. *Antioxidants & Redox Signaling* 21, 260–292.
- Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, Leonardi GC, Plodkowski AJ, Gupta H, Cherniack AD, Tolstorukov MY, Sharma B, Felt KD, Gainor JF, Ravi A, Getz G, Schalper KA, Henick B, Forde P, Anagnostou V, Jänne PA, Van Allen EM, Nishino M, Sholl LM, Christiani DC, Lin X, Rodig SJ, Hellmann MD and Awad MM (2022) Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. *JAMA Oncology* 8, 1160–1168.
- Richman SD, Hemmings G, Roberts H, Gallop N, Dodds R, Wilkinson L, Davis J, White R, Yates E, Jasani B, Brown L, Maughan TS, Butler R, Quirke P and Adams R (2022) FOCUS4 biomarker laboratories: From the benefits to the practical and logistical issues faced during 6 years of centralised testing. *Journal of Clinical Pathology* 76, 548.
- Rothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, Smith N, Villa S, Dransfield J, Clipson A, White D, Nessa K, Ferdous S, Howell M, Gupta A, Kilerci B, Mohan S, Frese K, Gulati S, Miller C, Jordan A, Eaton H, Hickson N, O'Brien C, Graham D, Kelly C, Aruketty S, Metcalf R, Chiramel J, Tinsley N, Vickers AJ, Kurup R, Frost H, Stevenson J, Southam S, Landers D, Wallace A, Marais R, Hughes AM, Brady G, Dive C and Krebs MG (2019) Utility of CtDNA to support patient selection for early phase clinical trials: The TARGET study. *Nature Medicine* 25, 738–743.
- Ruben MD, Wu G, Smith DF, Schmidt RE, Francey LJ, Lee YY, Anafi RC and Hogenesch JB (2018) A database of tissue-specific rhythmically expressed human genes has potential applications in circadian medicine. *Science Translational Medicine* 10, eaat8806.
- Salama AKS, Li S, Macrae ER, Park J-I, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP and Flaherty KT (2020) Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: Results of the NCI-MATCH trial subprotocol H. *Journal of Clinical Oncology* 38, 3895–3904.
- Sbaraglia M, Bellan E and Dei Tos AP (2021) The 2020 WHO classification of soft tissue tumours: News and perspectives. *Pathologica* 113, 70–84.
- Schack LMH, Naderi E, Fachal L, Dorling L, Luccarini C, Dunning AM, Head and Neck Group of the Radiogenomics Consortium, Danish Head and Neck Cancer Group (DAHANCA), Ong EHW, Chua MLK, Langendijk JA, Alizadeh BZ, Overgaard J, Eriksen JG, Andreassen CN and Alsner J (2022) A genome-wide association study of radiotherapy induced toxicity in head and neck Cancer patients identifies a susceptibility locus associated with mucositis. *British Journal of Cancer* 126, 1082–1090.

- Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M and Brauch H (2007) Breast Cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 25, 5187–5193.
- Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V and Kurzrock R (2015) Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 33, 3817–3825.
- Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB and Torres-Roca JF (2017) A genome-based model for adjusting radiotherapy dose (GARD): A retrospective, cohort-based study. *The Lancet. Oncology* 18, 202–211.
- Scott JG, Sedor Geoff, Scarborough JA, Kattan MW, Peacock J, Grass GD, Mellon EA, Thapa R, Schell M, Waller A, Poppen S, Andl G, Teer JK, Eschrich SA, Dilling TJ, Dalton WS, Harrison LB, Fox T and Torres-Roca JF (2021) Personalizing radiotherapy prescription dose using genomic markers of Radiosensitivity and Normal tissue toxicity in NSCLC. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer* 16, 428–438.
- Scott JG, Sedor Geoffrey, Ellsworth P, Scarborough JA, Ahmed KA, Oliver DE, Eschrich SA, Kattan MW and Torres-Roca JF (2021) Pan-Cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): A cohort-based pooled analysis. *The Lancet. Oncology* 22, 1221–1229.
- Sechidis K, Papangelou K, Metcalfe PD, Svensson D, Weatherall J and Brown G (2018) Distinguishing prognostic and predictive biomarkers: An information theoretic approach. *Bioinformatics* 34, 3365–3376.
- Seibold P, Webb A, Aguado-Barrera ME, Azria D, Bourquier C, Brengues M, Briers E, Bultjink R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning AM, Elliott RM, Fachal L, Farcy-Jacquet M-P, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson DS, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein BS, De Ruyscher D, De Santis MC, Schäfer J, Schnabel T, Sperk E, Symonds RP, Stobart H, Taboada-Valladares B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Ward T, Weissenberger C, West CML, Chang-Claude J and REQUITE consortium (2019) REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate Cancer. *Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology* 138, 59–67.
- Seligmann JF, Fisher DJ, Brown LC, Adams RA, Graham J, Quirke P, Richman SD, Butler R, Domingo E, Blake A, Yates E, Braun M, Collinson F, Jones R, Brown E, de Winton E, Humphrey TC, Parmar M, Kaplan R, Wilson RH, Seymour M and Maughan TS (2021) Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal Cancer: A randomized trial (FOCUS4-C) comparing Adavosertib (AZD1775) with active monitoring. *Journal of Clinical Oncology* 39, 3705–3715.
- Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B and Kurzrock R (2019) Molecular profiling of cancer patients enables personalized combination therapy: The I-PREDICT study. *Nature Medicine* 25, 744–750.
- Sjöström M, Chang SL, Fishbane N, Davicioni E, Zhao SG, Hartman L, Holmberg E, Feng FY, Speers CW, Pierce LJ, Malmström P, Fernö M and Karlsson P (2019) Clinicogenomic radiotherapy classifier predicting the need for intensified locoregional treatment after breast-conserving surgery for early-stage breast cancer. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 37, 3340–3349.
- Sjöström M, Fyles A, Liu F-F, McCreedy D, Shi W, Rey-McIntyre K, Chang SL, Feng FY, Speers CW, Pierce LJ, Holmberg E, Fernö M, Malmström P and Karlsson P (2023) Development and validation of a genomic profile for the omission of local adjuvant radiation in breast cancer. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 41, 1533–1540.
- Slikker W (2018) Biomarkers and their impact on precision medicine. *Experimental Biology and Medicine (Maywood, N.J.)* 243, 211–212.
- Spranger S, Bao R and Gajewski TF (2015) Melanoma-intrinsic β -catenin signalling prevents anti-tumour immunity. *Nature* 523, 231–235.
- Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JM, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJ, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG and Feng FY (2023) Genomic classifier performance in intermediate-risk prostate cancer: Results from NRG Oncology/RTOG 0126 randomized phase III trial. *International Journal of Radiation Oncology, Biology, Physics* 117, 370.
- Stockley TL, Oza AM, Berman HK, Leigh NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao M-S, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak ARA, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL and Bedard PL (2016) Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: The Princess Margaret IMPACT/COMPACT trial. *Genome Medicine* 8, 109.
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. *The New England Journal of Medicine* 352, 987–996.
- Subbiah V (2023) The next generation of evidence-based medicine. *Nature Medicine* 29, 49–58.
- Sun H, Ren P, Chen Y, Lan L, Yan Z, Yang Y, Wang B, Wang C, Li Yanwei, Li L, Zhang Y, Li Yanyang, Wang Z, Pan Z and Jiang Z (2023) Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung Cancer: A real-world study. *BMC Cancer* 23, 198.
- Suski JM, Braun M, Strmiska V and Sicinski P (2021) Targeting cell-cycle machinery in Cancer. *Cancer Cell* 39, 759–778.
- Tang Z, Zeng Q, Li Y, Zhang X, Ma J, Suto MJ, Xu B and Yi N (2017) Development of a radiosensitivity gene signature for patients with soft tissue sarcoma. *Oncotarget* 8, 27428–27439.
- Thomas G, Eisenhauer E, Bristow RG, Grau C, Hurkmans C, Ost P, Guckenberger M, Deutsch E, Lacombe D, Weber DC and European Organisation for Research and Treatment of Cancer (EORTC) (2020) The European Organisation for Research and Treatment of Cancer, state of science in radiation oncology and priorities for clinical trials meeting report. *European Journal of Cancer (Oxford, England: 1990)* 131, 76–88.
- Tie J (2023) Triaging suspected cancer with a multi-Cancer early detection blood test. *The Lancet Oncology* 24, 710–711.
- Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, Wong R, Shapiro J, Lee M, Harris S, Khattak A, Burge M, Harris M, Lynam J, Nott L, Day F, Hayes T, McLachlan SA, Lee B, Ptak J, Silliman N, Dobbyn L, Popoli M, Hruban R, Lennon AM, Papadopoulos N, Kinzler KW, Vogelstein B, Tomasetti C, Gibbs P and DYNAMIC Investigators (2022) Circulating tumor DNA analysis guiding adjuvant therapy in stage II Colon Cancer. *The New England Journal of Medicine* 386, 2261–2272.
- Tivey A, Church M, Rothwell D, Dive C and Cook N (2022) Circulating tumour DNA - looking beyond the blood. *Nature Reviews. Clinical Oncology* 19, 600–612.
- Tonelli MR and Shirts BH (2017) Knowledge for precision medicine: Mechanistic reasoning and methodological pluralism. *JAMA* 318, 1649–1650.
- Topol EJ (2014) Individualized medicine from Prewomb to tomb. *Cell* 157, 241–253.
- Van Cutsem E, Köhne C-H, Hitre E, Zulski J, Chang Chien C-R, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J and Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *The New England Journal of Medicine* 360, 1408–1417.
- van Tilburg CM, Pfaff E, Pajtlér KW, Langenberg KPS, Fiesel P, Jones BC, Balasubramanian GP, Stark S, Johann PD, Blattner-Johnson M, Schramm K, Dikow N, Hirsch S, Sutter C, Grund K, von Stackelberg A, Kulozik AE,

- Lissat A, Borkhardt A, Meisel R, Reinhardt D, Klusmann J-H, Fleischhack G, Tippelt S, von Schweinitz D, Schmid I, Kramm CM, von Bueren AO, Calaminus G, Vorwerk P, Graf N, Westermann F, Fischer M, Eggert A, Burkhardt B, Wößmann W, Nathrath M, Hecker-Nolting S, Frühwald MC, Schneider DT, Brecht IB, Ketteler P, Fulda S, Koscielniak E, Meister MT, Scheer M, Hettmer S, Schwab M, Tremmel R, Øra I, Hutter C, Gerber NU, Lohi O, Kazanowska B, Kattamis A, Filippidou M, Goemans B, Zwaan CM, Milde T, Jäger N, Wolf S, Reuss D, Sahn F, von Deimling A, Dirksen U, Freitag A, Witt R, Lichter P, Kopp-Schneider A, Jones DTW, Molenaar JJ, Capper D, Pfister SM and Witt O (2021) The pediatric precision oncology INFORM registry: Clinical outcome and benefit for patients with very high-evidence targets. *Cancer Discovery* **11**, 2764–2779.
- Vo KT, Sabnis AJ, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Jaju A, Fox E, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel N and Parsons DW (2022) Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG pediatric MATCH trial arm J (APEC1621J). *Journal of Clinical Oncology* **40**, 3009–3009.
- Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, Mani S and Redinbo MR (2010) Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. *Science (New York, N.Y.)* **330**, 831–835.
- Wang J, Wang H and Qian H (2018) Biological effects of radiation on Cancer cells. *Military Medical Research* **5**, 20.
- Webb AJ, Harper E, Rattay T, Aguado-Barrera ME, Azria D, Bourgier C, Brengues M, Briers E, Bultijnck R, Chang-Claude J, Choudhury A, Cicchetti A, De Ruyscher D, De Santis MC, Dunning AM, Elliott RM, Fachal L, Gómez-Caamaño A, Gutiérrez-Enriquez S, Johnson K, Lobato-Busto R, Kerns SL, Post G, Rancati T, Reyes V, Rosenstein BS, Seibold P, Seoane A, Sosa-Fajardo P, Sperk E, Taboada-Valladares B, Valdagni R, Vega A, Veldeman L, Ward T, West CM, Symonds P, Talbot CJ and REQUITE Consortium (2022) Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort. *eBioMedicine* **84**, 104269.
- Wegman P, Vainikka L, Stål O, Nordenskjöld B, Skoog L, Rutqvist L-E and Wingren S (2005) Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast Cancer patients. *Breast Cancer Research* **7**, R284–R290.
- Weinstein JN, Collisson EA, Mills GB, Shaw KM, Ozenberger BA, Ellrott K, Shmulevich I, Sander C and Stuart JM (2013) The cancer genome atlas Pan-Cancer analysis project. *Nature Genetics* **45**, 1113–1120.
- Werbrouck C, Evangelista CCS, Lobón-Iglesias M-J, Barret E, Le Teuff G, Merlevede J, Brusini R, Kergrohen T, Mondini M, Bolle S, Varlet P, Beccaria K, Boddaert N, Puget S, Grill J, Debily M-A and Castel D (2019) TP53 pathway alterations drive radioresistance in diffuse intrinsic pontine gliomas (DIPG). *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* **25**, 6788–6800.
- West C, Azria D, Chang-Claude J, Davidson S, Lambin P, Rosenstein B, De Ruyscher D, Talbot C, Thierens H, Valdagni R, Vega A and Yuille M (2014) The REQUITE project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in Cancer survivors. *Clinical Oncology (Royal College of Radiologists (Great Britain))* **26**, 739–742.
- West Catharine, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, Bentzen S, Burnet N, Chang-Claude J, Chuang E, Coles C, De Ruysck K, De Ruyscher D, Dunning A, Elliott R, Fachal L, Hall J, Haustermans K, Herskind C, Hoelscher T, Imai T, Iwakawa M, Jones D, Kulich C, EQUAL-ESTRO, Langendijk J-H, O'Neils P, Ozsahin M, Parliament M, Polanski A, Rosenstein B, Seminara D, Symonds P, Talbot C, Thierens H, Vega A, West Catherine and Yarnold J (2010) Establishment of a Radiogenomics consortium. *International Journal of Radiation Oncology, Biology, Physics* **76**, 1295–1296.
- Wu S, Xu J, Li G and Jin X (2022) Integrating radiosensitivity gene signature improves glioma outcome and radiotherapy response prediction. *Medicina (Kaunas, Lithuania)* **58**, 1327.
- Xu C, Tang X, Qu Y, Keyoumu S, Zhou N and Tang Y (2016) UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal Cancer. *Cancer Chemotherapy and Pharmacology* **78**, 119–130.
- Ye Y, Xiang Y, Ozguc FM, Kim Y, Liu C-J, Park PK, Hu Q, Diao L, Lou Y, Lin C, Guo A-Y, Zhou B, Wang L, Chen Z, Takahashi JS, Mills GB, Yoo S-H and Han L (2018) The genomic landscape and Pharmacogenomic interactions of clock genes in Cancer chronotherapy. *Cell Systems* **6**, 314–328.e2.
- Yi Y, Lu W, Shen L, Wu Y and Zhang Z (2023) The Gut microbiota as a booster for radiotherapy: Novel insights into radio-protection and radiation injury. *Experimental Hematology & Oncology* **12**, 48.
- Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA-D, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL and Feng FY (2016) Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate Cancer: A matched, retrospective analysis. *The Lancet. Oncology* **17**, 1612–1620.
- Zhong H and Prentice RL (2010) Correcting 'Winner's curse' in odds ratios from genomewide association findings for Major complex human diseases. *Genetic Epidemiology* **34**, 78–91.
- Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L and Christiani DC (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung Cancer patients treated with platinum-based chemotherapy. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* **10**, 4939–4943.
- Zhou Y and Lauschke VM (2022) The genetic landscape of Major drug metabolizing cytochrome P450 genes—An updated analysis of population-scale sequencing data. *The Pharmacogenomics Journal* **22**, 284–293.
- Zhou J, Wang J, Zhang X and Tang Q (2021) New insights into Cancer chronotherapies. *Frontiers in Pharmacology* **12**, 741295.